

AD\_\_\_\_\_

Award Number: DAMD17-98-1-8284

TITLE: Designer T Cells for Breast Cancer Therapy: Phase I  
Studies

PRINCIPAL INVESTIGATOR: Richard P. Junghans, Ph.D., M.D.

CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center  
Boston, Massachusetts 02215

REPORT DATE: July 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020124 256

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)

2. REPORT DATE  
July 2001

3. REPORT TYPE AND DATES COVERED  
Annual (01 Jul 00 - 30 Jun 01)

4. TITLE AND SUBTITLE

Designer T Cells for Breast Cancer Therapy: Phase I Studies

5. FUNDING NUMBERS

DAMD17-98-1-8284

6. AUTHOR(S)

Richard P. Junghans, Ph.D., M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)

Beth Israel Deaconess Medical Center  
Boston, Massachusetts 02215

E-Mail: junghans@hms.harvard.edu

8. PERFORMING ORGANIZATION  
REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)

U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING  
AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT

Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

In the present report we describe studies using chimeric immune receptors consisting of an antibody fragment against the CEA tumor antigen joined to signaling portions of the T cell receptor (IgTCR). The antibody fragment confers CEA specificity to the receptor, while the signaling domains transmit T cell activation signals. These receptors allow the T cells (designer T cells) to bypass immune tolerance to CEA and to activate effector functions in a tumor specific manner. We have partially completed a phase I study using IgTCR-modified designer T cells. These studies demonstrate the specific signaling molecules activate specific T cell effector functions in a tumor specific manner. The study will be completed on a continuing no-cost extension with the funds allocated.

14. SUBJECT TERMS

Breast Cancer

15. NUMBER OF PAGES

85

16. PRICE CODE

17. SECURITY CLASSIFICATION  
OF REPORT

Unclassified

18. SECURITY CLASSIFICATION  
OF THIS PAGE

Unclassified

19. SECURITY CLASSIFICATION  
OF ABSTRACT

Unclassified

20. LIMITATION OF ABSTRACT

Unlimited

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	8
References.....	9
Appendices.....	10

#### 4. INTRODUCTION

Carcinoembryonic antigen (CEA) is a tumor-associated antigen which is expressed on  $\approx 30$ -60% of metastatic breast tumors. The purpose of this research is to develop a new type of cancer therapy using autologous T cells modified with a chimeric immunoglobulin T cell receptor (IgTCR) directed against CEA + tumors. The specific objectives are to:

1. Complete setup for therapy.
2. Apply IgTCR-modified cells in a phase I clinical study in patients with metastatic CEA + breast tumors

In addition, to the above we have also carried out basic research efforts to create second-generation reagents that will enhance the therapy for future phase II/III studies.

## **5. BODY**

The following activities were undertaken under the current year no-cost extension to the above referenced grant. It is noted that only two years of funding were provided by the DOD, whereas the task list was stated for the entire 4 year requested funding period. Accordingly, certain of the tasks were abandoned due to lack of funding, as indicated below.

### **I. Lab and clinical set up for therapy.**

This was previously reported as completed.

However, we have been mandated to redo this step during the recent year by our local institution (not by the FDA), with a patient-dedicated facility. This was previously in a shared-use facility according that was acceptable under FDA specifications. We have hired new staff and are presently re-establishing this facility. We anticipate certification for resumption of patient treatments in 9/2001.

### **II. Phase I clinical trial**

This trial was partially completed but interrupted due to reasons mentioned in the prior report. In the past year, we have responded to requests for redesign of the Cell Transduction Facility (CTF) for patient sample preparation. We have also established a DSMB to conduct patient monitoring on this gene therapy study. With various other administrative responses and design changes (only very modest changes to the treatment protocol), we are ready to resume the study in 9/2001 and should complete the trial within the coming year. There remain 5 patients to treat on the phase I study.

All patient care funds have been preserved, and will be applied to complete the phase I tests.

### **III. Phase II study**

Funding was not provided to support this study. This task is abandoned.

### **IV. Phase II study +IL2**

Funding was not provided to support this study. This task is abandoned.

### **V. Laboratory studies for therapy improvement.**

#### **A. Prepare improved VPCs.**

Completed in prior report.

#### **B. Prepare improved helper cell lines.**

Funding was not provided to support this effort. This task is abandoned.

C. Prepare CEA-IgG chimeric protein.

This product has been designed and cloned. It has yet to be expressed, which will be conducted during the next year of this no-cost extension.

## **6. KEY RESEARCH ACCOMPLISHMENTS**

- Re-certify newly patient dedicated Cell Transduction Facility.
- New staff hiring and training.
- Established DSMB.
- Patient Treatment objectives deferred. To be accomplished with remaining funds.
- Preparation of CEA-IgG construct.

## **7. REPORTABLE OUTCOMES**

- Publications:

Beecham EJ, Ma QZ, Ripley R, Junghans RP. Coupling of CD28 co-stimulation to IgTCR molecules: Dynamics of T cell proliferation and death. *J Immunother* 2000;23:631-42.

Ma QZ, Gonzalo-Danganan R, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. In Harrison P (ed) Cancer Chemotherapy & Biological Response Modifiers – Annual 20 Oxford: Elsevier Science. 2001: in press.

## **8. CONCLUSIONS**

The key clinical efforts of this study are deferred and will be completed in the coming year with conserved Department of Defense funds under this no-cost extension.



## **9. REFERENCES**

None.

## 10. APPENDICES

### A. Manuscripts

Beecham EJ, Ma QZ, Ripley R, Junghans RP. Coupling of CD28 co-stimulation to IgTCR molecules: Dynamics of T cell proliferation and death. *J Immunother* 2000;23:631-42.

Ma QZ, Gonzalo-Danganzo R, Junghans RP. Genetically engineered T cells as adoptive immunotherapy of cancer. In Harrison P (ed) Cancer Chemotherapy & Biological Response Modifiers – Annual 20 Oxford: Elsevier Science. 2001: in press.

*in Cancer Chemotherapy and Biological  
Response Modifiers, Annual 20, in press.*

**Genetically Engineered T Cells as Adoptive Immunotherapy of Cancer**

Qiangzhong Ma, Ph.D., Rosa M. Gonzalo-Daganzo, Ph.D., Richard P. Junghans<sup>1</sup>, Ph.D., M.D.

Biotherapeutics Development Lab, Harvard Institute of Human Genetics and Division of  
Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical  
School, Boston, MA 02215

<sup>1</sup>Address correspondence to: Richard P. Junghans, Ph.D., M.D., 4 Blackfan Circle, Room  
403, Harvard Institutes of Medicine, Boston, MA 02215 Tel: (617) 432-7004; Fax: (617)  
432-7007; e-mail: [junghans@hms.harvard.edu](mailto:junghans@hms.harvard.edu)

## **1. Introduction**

### ***1.1. Immunotherapy***

It has been a major focus of modern cancer research to explore the potential of immune system components to combat malignant disease. This strategy has been two-pronged, exploiting on the one hand the humoral immune system as represented by antibodies, and on the other the cellular immune system as represented by lymphokine activated killer cells and tumor infiltrating lymphocytes. In general, antibodies have the capability to supply specificity, but suffer from lack of potency. Cellular therapies, in contrast, have potency with potentially lethal consequences if not closely regulated, whereas specificity is often lacking.

### ***1.2. Adoptive immunotherapy***

Evidence from experimental animal tumor models and cancer patients showed that cellular rather than humoral immune responses were responsible for the rejection of tumor [1, 2]. Effective cellular immune therapy in cancer needs three essential components:

1. Tumor recognition (specificity)
2. Cytotoxicity against tumor cells (potency)
3. Sustained activity in the tumor bed (effector cell survival/proliferation)

These components will be referred to throughout this essay. To address these features, alternative approaches explored in recent years have been to genetically engineer T cells to express cytokines or chimeric receptors for tumor antigens to make the T cells either more potent or more specific. By way of background, a brief history of the use of LAK

cells and TILs will be presented while the remainder of this chapter will focus on the genetic manipulation of T cells.

#### *1.2.1. LAK cells*

Early studies with adoptive immunotherapy applied lymphokine activated killer (LAK) cells derived by ex vivo amplification of autologous lymphocytes with interleukin-2 (IL-2) [3]. Large numbers of cells were infused, as many as  $4 \times 10^{11}$ , in a regimen with co-administration of IL-2. Substantial numbers of responses were obtained in renal cell carcinoma and melanoma (21-35% CR+PR), but the added benefit of LAK + IL-2 versus IL-2-alone, which also generated responses, was marginal [4]. Substantial toxicities were generated, but these toxicities did not appear to differ from those of the IL-2 alone. The LAK treatments were applied at maximum tolerated or maximum practical doses, yet a conclusive benefit of the LAK cell treatments could not be shown independent of the co-administered IL-2.

Whereas the LAK cells were shown to demonstrate cytotoxicity against tumor cells in vitro against cell lines [5], and in animal models using such cell lines [6], their in vivo application in humans lacked sufficient specificity and potency. However, the viability of such cells was successfully sustained by IL-2 administration, which causes LAK cell expansion in vivo [7].

#### *1.2.2. TILs*

When responses were observed with IL-2 therapy alone, this was correlated with T cell infiltration and proliferation in the tumor bed. It was hypothesized that these T

infiltrating lymphocytes (TILs) were tumor-specific, and part of a natural immune recognition that did not by itself translate into tumor eradication. With the IL-2 stimulus, this native recognition was expanded and efficacy, in a few cases, was achieved. The tumor specificity of the responding T cells was supported by diverse studies, leading to discovery of a large number of new antigens, mainly in melanoma [8]. Curiously, these antigens are typically normal, unmutated proteins derived from normal melanocytes; the basis for their immunogenic character in melanoma is controversial and still under study.

The next generation of adoptive immunotherapies after LAK cells was based on isolating these TILs from tumor specimens, principally in melanoma, and expanding those cells *ex vivo*, by stimulating the cells with autologous tumor and IL-2. In animal studies, TILs were shown to be 10-100 times more potent than LAK cells in reducing lung metastases [9]. Human trials in melanoma showed TILs trafficking to tumor sites after injection [10-13]. Although the absolute numbers of T cells trafficking to tumor were small, response rates in the range of 30-35% were obtained [14], which were superior to the rates of 20% previously achieved in melanoma with IL-2 alone or LAK + IL-2 [4]. However, the infrequency of durable remissions (<5%) was inadequate to justify the costs and toxicities of therapy.

In patients with cures or major responses with TILs or IL-2 therapy, the three elements of specificity, potency and proliferation were evidently present. Correlates of response in the TILs studies were (1) relative potency of TILs by *in vitro* cytotoxicity tests, (2) larger numbers of cells infused, and (3) rapid expansion rate of TILs in culture. Whereas cytotoxicity was demonstrated *ex vivo* by TILs for most patients, this potency was nevertheless inadequate for the task of eliminating tumor masses *in vivo* in the majority of cases. Examining these three components, the specificity of the TILs was apparent from the fact that the *ex vivo* T cell expansion was dependent upon the presence of

patient tumor. The potency of patient TILs varied, and this appeared to be a key factor. Finally, the predictive value of the proliferation rate of the cells prior to infusion suggested that the viability and expansion within the tumor was essential also, and insufficient for most patients.

### *1.3. Need for new approaches*

Recognition by T cells may have diverse outcomes, depending upon a number of variables, some of which are still subject to definition. One factor in recognition is the avidity and number of interactions of the TCR for antigen [15, 16]. Where a TCR poorly recognizes antigen, or the number of presented antigen molecules (peptides in MHC) is low, the likelihood that recognition will lead to effective signal generation (for cytotoxicity, cytokine secretion or proliferation) is reduced. Furthermore, it is only the rare setting (e.g., melanoma) in which there is a tumor antigen that generates immune recognition that is not already fully tolerized in vivo. Accordingly, strategies have evolved in order to overcome these deficiencies of the earlier efforts in adoptive immunotherapy, by genetic manipulations that alter the response of patient effector cells to tumor, by increasing potency, specificity and/or proliferation. These are discussed in this chapter.

## **2. Genetic Manipulation of T Cells**

### *2.1. Transduction Methods*

The efficient gene transfer into effector cells is the prerequisite for the application of genetic engineered T cells strategy for adoptive immunotherapy. Numerous techniques are available for gene transfer into mammalian cells [17]. Among them, retroviral based gene transfer is the most effective means presently available for transduction of T cells with high frequencies and stable gene expression.

Retroviruses are RNA viruses that are capable of stably integrating DNA within the host genome. Retroviral vectors for gene transfer have been constructed by substituting the gene of interest in place of the viral protein coding regions. These vectors are packaged into retroviral particles using packaging cell lines (Figure 1) [18]. The envelope protein determines the host range of the retroviruses.

The development of packaging cell lines that use alternative envelope genes has resulted in significant advances in the ability to transduce lymphocytes. Specifically, retroviral vectors packaged with the envelope from the gibbon ape leukemia virus (GALV) are capable of transducing T cells with significantly higher efficiencies [19, 20]. Retroviruses require cell division for integrating into the host genome. Typically T cells are activated to proliferate by anti-CD3 antibody. Optimal T cell activation by anti-CD3 plus anti-CD28 can significantly enhance the gene transfer efficiency into human T cells [21]. The presence of fibronectin derived peptide during transduction [22] and application of 1 hour of centrifugation at 1000g can also significantly improve the gene transfer efficiency [19, 23]. By optimized conditions, the transduction efficiency can reach as high as 35-70% of T cells in routine experiments [24, 25].

Recently, T cells modification and expansion by direct DNA transfer has also been shown on a clinical scale [26]. Methods for efficient gene transfer are likely to evolve significantly over the next few years.

## *2.2. Clinical studies with gene-marked T cells*

Before testing clinically the T cells that have been genetically modified with functional genes, Rosenberg and colleagues assayed the safety and viability of T cells modified with a marking gene by retroviral vector in humans [27, 28]. In these initial studies, a retroviral vector (LNL6) derived from the Moloney murine leukemia with the replication



genes deleted, was constructed to express the gene of the bacterial enzyme neomycin phosphotransferase (Neo<sup>R</sup>) (Figure 2A) [29]. This enzyme inactivates G418, a drug toxic to eukaryotic cells that can be used for ex vivo selection. Melanoma-derived TILs were transduced with LNL6 retroviral vector and selected in G418 and expanded. Ten patients were treated with their own autologous gene-marked T cells. Safety assays were performed on the viral supernatant of transduced TILs and on the sera from patients to rule out the existence of replication-competent virus or the malignant transformation of the modified TILs [29]. These modified TILs were traced by polymerase chain reaction in peripheral blood of patients for the first 21 days after infusion and up to 64 days in tumor deposits [27]. Other gene-marking clinical trials were performed by Favrot and Philip [30], Riddell et al [31] and Lotze et al [32], all supporting the safety and lack of toxicity of retroviral gene transduction for human cells.

A primary rationale for the use of TILs has been to exploit the natural homing properties of these immune cells to traffic to tumor deposits [10]. Human trials in melanoma showed TILs trafficking to tumor sites with threefold increase related to non-specific lymphocyte [10-12]. However, Economou et al in a double gene-marking TILs human trial, using marked TILs and PBLs reported no evidence of preferential trafficking of TILs versus PBLs to tumors [13]. In this study, TILs and PBLs from nine patients were activated, expanded in parallel and transduced with different retroviral vectors (LNL6 and G1Na respectively) expressing the Neo<sup>R</sup> gene. Although some patients did experience dramatic antitumor responses, the modified TILs and PBLs were detected in both tumor and normal tissue biopsies without any evidence for preferential TIL trafficking to tumor.

### **3. Engineering T Cells with Cytokine Genes**

Adoptive immunotherapy with LAK cells and later with TILs has shown the need for co-administration of exogenous IL-2 in order to achieve a clinically effective response.

While this cytokine is responsible and indispensable for sustaining the proliferation and survival of the effector cells in vivo, the toxicity in humans is high. Efforts have been made to improve by genetic modification these immune effector cells to fight against cancer. Some of these initiatives have focused on making T cells independent of exogenous IL-2, enhancing its sensitivity to IL-2, as well as increasing the antitumor effect by super-expression of tumor necrosis factor (TNF) by such effectors.

#### *3.1. Pre-clinical studies*

First described in the late 1980's, the insertion and constitutive expression of the IL-2 gene in a murine T cell line was shown to enable them to grow in an autocrine fashion [33, 34]. Moreover, retroviral expression of the IL-2 gene in human T cell clones showed that these cells retained their antigen specificity and expanded in an IL-2-independent fashion [35]. These investigators also reported a T cell line expressing a chimeric receptor consisting of the extracellular domain (ECD) of the erythropoietin (Epo) receptor and the intracellular signaling domains of the  $\beta$  and  $\gamma$  subunits of IL-2 receptor [36]. These T cells became Epo responsive, demonstrating a functional activation of the IL-2 signal pathway through this chimeric receptor.

Furthermore, genetically modified human CD8<sup>+</sup> CTLs expressing a chimeric gene of GM-CSF and IL-2 receptors were shown upon antigen binding to secrete sufficient GM-CSF to support proliferation via an autocrine growth loop in the absence of IL-2, whereas normal CTLs have no receptor for GM-CSF and normally are absolutely dependent on

IL-2 for growth and viability. By this design, modified CD8<sup>+</sup> CTLs would have a helper as well as a cytolytic activity, eliminating the necessity of an additional T cell population. This promising approach has been tested so far only in vitro [37].

### *3.2. Clinical Studies*

TNF has shown efficacy as an anti-tumor cytokine capable of inducing regression of experimental murine tumors if adequate levels are achieved [38, 39]. However, the systemic dose required to obtain the desired anti-tumor effect is too toxic in humans. One approach to circumvent this problem was the engineering of TNF-transduced TILs to increase their potency with local cytokine secretion in the tumor. The LNL6 retroviral vector was tested by Hwu et al in a phase I clinical trial without safety or toxicity problems [40, 41]. The vector contained both the human TNF- $\alpha$  gene under the control of LTR retroviral promoter and the Neo<sup>R</sup> gene under the SV40 early region promoter. Nevertheless, the level of TNF secretion was almost 30-fold lower than expected when compared to a tumor cell line transduced with the same vector.

In an attempt to improve TNF production, a new version of the vector was engineered by replacing the transmembrane region of the TNF with the signal peptide from IFN- $\gamma$  (Figure 2B) [29], that increased five-fold the production of TNF in transduced TILs compared to the original vector [42]. This construct was applied in a phase I clinical trial. Although responses were reported, response rates were not notably different versus unmodified TILs alone [40].

Engineering TILs with cytokine genes were among the first attempts to apply gene therapy techniques. Several human studies have reported that retroviral transduction of these immune effector cells with marking and/or cytokine genes is a safe and non-toxic means of therapy for human use. Despite the potential advantages, the expression of

foreign genes in lymphocytes for active cytotoxic secretion is still low and in need further improvement. Other features that could improve the success of adoptive immunotherapy are the enhancement of the migration properties to tumor and the augmentation of tumor specificity and targeting as described in the following section.

#### **4. Engineering T Cells with Tumor Specificity by Chimeric Receptors (“Designer T Cells”)**

Effective anti-tumor immunity usually cannot be induced due to lack of immunogenicity of the tumor cells. Thus, augmentation of immune effector functions by the infusion of tumor-reactive T cells represents a potentially highly specific modality for the treatment of cancer [43].

T cells conduct their immune functions through their antigen specific receptor, TCR-CD3 complex (Figure 3, right) [44]. The TCR exists in two types of heterodimers composed of two polypeptide chains:  $\alpha$ - $\beta$  (or, in some cases,  $\gamma$ - $\delta$ ). Each chain of the  $\alpha$ - $\beta$  TCR is composed of a variable region (V) and a constant region (C). The variable region determines the antigen binding specificity of the TCR. The TCR heterodimer is associated with the CD3 complex, which is composed of a group of polypeptide chains: two heterodimers of  $\gamma$ - $\epsilon$  and  $\delta$ - $\epsilon$  and one homodimer of  $\zeta$ - $\zeta$ . The CD3 complex is important for both the functional expression of TCR on the T cell surface and also for the transduction of the specific signal that is initiated from the TCR.

Upon ligation with the antigenic peptides presented by major histocompatibility complex (MHC) on their target cells, the T cells can be activated to result in cell proliferation, cytokine secretion and cytotoxicity [45, 46].

The antigenic peptides presented by the MHC on the tumor surface and the specific T cells that can react with a particular antigenic peptide are technically difficult to identify and isolate [47]. Hence, it is of considerable practical interest to be able to alter the specificity of T cells, allowing them to recognize specific antigens on tumor cells, to make tumor-reactive T cells for current use. To achieve this, an approach has been developed by genetically engineering T cells to express chimeric receptors that will endow the T cells with a neo-specificity, variously referred to as “designer T cells”, “universal receptor (UR) T cells”, or “T-bodies”. This is accomplished either by directly modifying the TCR or by linking ligand-binding domains derived from antibodies or other receptors with the signaling domains derived from the TCR-CD3 or other activating receptors. One of the currently favored immunoglobulin-T cell receptor (IgTCR) configurations is shown in Figure 3. However, many different designs have been examined, as shall be discussed. Designer T cells modified with these receptors recognize and kill tumor cells through the newly grafted chimeric receptors in a MHC-unrestricted fashion, which is of particular advantage when preparing reagents for wide clinical applicability.

For clinical application, patient T cells would be transduced with the chimeric genes, expanded ex vivo and then reinfused into the patients (Figure 4). In concept, cells would

traffick through the body with activation at the tumor site and induce tumor rejection, either by direct cytotoxicity and/or by causing a local inflammatory response [25]. This approach has the potential to treat a wide range of cancers by adoptive immunotherapy. In the past decade, T cells have been modified using this technology to create diverse kinds of chimeric receptors against a large number of different tumor models.

#### *4.1. Structure of chimeric receptors*

The chimeric receptor used to alter the specificity of T cells must possess two different functions: (1) to bind to a predetermined target antigen and (2) to activate the genetically modified T cells. Currently two types of chimeric receptors have been designed. One type is by grafting the TCR chains with a new antigen-binding domain. In this design, the activation signals are transmitted through the native TCR-CD3 complex. The other type is by directly linking the antigen-binding domain with a signaling chain that can deliver signal to the T cells necessary for T cell effector functions.

##### *4.1.1. Antigen-binding domain*

The antigen-binding domain can be either derived from antibody or TCR against the targeted antigen on the target cell surface, or derived from a ligand that can bind with a receptor on the target cell surface.

##### *4.1.1.1. Derived from antibody*

With current techniques, monoclonal antibody (mAb) against any kind of antigen can be readily derived, and such mAbs have been generated that are specific to different tumor antigens.

Kuwana et al was the first group to make immunoglobulin-T cell receptor (IgTCR) chimeric receptors. By using the variable regions from an anti-phosphorylcholine (PC) antibody and the constant regions from the TCR, they constructed two pairs of chimeric genes:  $V_L-C_\beta$  and  $V_H-C_\alpha$  genes, and  $V_L-C_\alpha$  and  $V_H-C_\beta$  genes [48], which functionally transmitted T cell signaling via the new PC specificity.

The specificity of antibodies for complex antigens (i.e., protein) typically relies on both the  $V_H$  and  $V_L$  regions, in which both the  $V_H$  and  $V_L$  are required to be incorporated into the chimeric receptors. Sometimes, however, the recognition specificity of an antibody may be contributed mainly by either the  $V_H$  or  $V_L$  region, typically with small molecules or haptens. In such a case, one single chain of  $V_H$  or  $V_L$  may be used for construction of the chimeric receptor. For example, the  $V_H$  regions from both the anti-trinitrophenyl (TNP) mAb [41, 49] and an anti-phosphorylcholine mAb [50] are such instances of single V molecules that have been used for construction of chimeric receptors.

The Fab fragment of antibody can also be used as antigen-binding domain for construction of chimeric receptors. Nolan et al [44] successfully expressed anti-CEA Fab- $\epsilon$  and Fab- $\zeta$  chimeric receptors on T cells that conferred CEA specificity whereas Yun et al [51] similarly modified T cells with a Fab for ganglioside GD3 specificity. In this, the

Fd chain ( $V_H$ - $C_{H1}$ ) was genetically joined directly to the  $\epsilon$  or  $\zeta$  chain, whereas the L chain ( $V_L$ - $V_H$ ) was separately expressed in the T cells with successful assembly into native Fab configuration. However, this strategy, like that of Kuwana et al, required the expression of two separate constructs in the T cells, and is therefore technically more cumbersome than the single chain constructs (below). Fab does have the advantage, however, of preserving the native antibody affinity that may often be lost in single chain Fv (sFv) constructs [52].

The design of a single-chain fragment of variable regions (sFv) [53, 54] in the construction of the chimeric receptor overcomes the limitation of the two-constructs strategy [55, 56]. The sFv consists of the  $V_H$  and  $V_L$  regions derived from an antibody molecule that are joined via a flexible peptide linker. Ideally, the recombinant sFv retains the antigen binding specificity and affinity of the parent antibody [57], but may also suffer moderate [58] or major affinity losses [52]. Because the sFv are substantially more convenient for T cell gene expression, however, they have come to be the predominant constructs in the preparation of the chimeric receptors.

#### *4.1.1.2. Derived from TCR*

TCR recognize antigenic peptides presented in the context of major histocompatibility complex (MHC) molecules. Similar to the use of the variable regions derived from antibody to generate the chimeric receptor, the variable regions of the TCR may also be used as recognition domains to generate chimeric receptors against TCR-specific peptide antigens. These products are, however, subject to MHC restriction, i.e., applicable only



for individuals with a specific HLA type. By using the variable regions derived from the TCR from a melanoma-specific cytotoxic human T cell line, Willemsen et al generated a single-chain TCR recognition domain by linking the  $V_{\alpha}$  and  $V_{\beta}$  with a linker as well as a two-chain TCR which expressed the  $V_{\alpha}$  and  $V_{\beta}$  separately, finally linked to the CD3 $\zeta$  signaling chain. These grafted chimeric receptors redirected T cells to recognize MAGE-A1 on HLA-A1<sup>+</sup> target cells [59]. HLA-A1 is represented in 40% of Caucasians, the primary disease population in melanoma, which means that even an MHC-dependent peptide can be widely targeted with a single, specific TCR construct for this group of subjects.

#### *4.1.1.3. Derived from ligand*

The binding domain derived from the ligand of a receptor may also be used to generate designer T cells that can specifically target receptor-expressing cells. Romeo et al fused CD4 with the TCR CD3 chains or with the Fc receptor  $\gamma$  chain. CD4 is the natural ligand for the gp120 HIV envelope protein. These receptor chimeras successfully redirected CD8<sup>+</sup> cytotoxic T lymphocytes (CTLs) to specifically recognize and lyse HIV-infected T cells [60]. Similarly, Altenschmidt et al used the binding domain from the human heregulin  $\beta$ 1, which is the ligand to the erbB-3 and erbB-4 receptors, to generate a chimeric receptor that redirected T cells to recognize and kill erbB-3 and erbB-4 positive target cells [61]. Using the binding domain of IL-13, Kahlon and Jensen generated designer T cells that recognize and kill IL-13R<sup>+</sup> malignant glioma and renal cell carcinoma [62].

#### *4.1.2. Signaling domain*

The antigen binding domain, however constructed, is ultimately linked to the cell signaling apparatus (1) by association with independent signaling molecules (e.g., modified TCR with the native CD3 complex) or (2) by direct genetic linkage to cellular signaling chains.

##### *4.1.2.1. Association with signaling chain*

T cells use the T cell receptor (TCR) for recognition of antigen on their target cells. The TCR associates non-covalently with signaling molecules of the CD3 complex (Figure 3). It is evident that specificity of T cells may be directed to new antigens by grafting the TCR  $\alpha$  and  $\beta$  chains with different antigen specificities. In the very first IgTCR application, Kuwana et al successfully expressed two pairs of chimeric genes,  $V_L-C_\beta$  and  $V_H-C_\alpha$  genes, and  $V_L-C_\alpha$  and  $V_H-C_\beta$  genes in the murine EL4 T cell line. Increases in the concentration of cytoplasmic calcium ion were observed in the transduced EL4 cells when they contacted  $PC^+$  bacteria [48].

Becker et al generated a hybrid IgTCR  $V_H-C_\alpha$  gene using  $V_H$  from a digoxin-specific antibody. This hybrid  $V_H-C_\alpha$  protein was expressed on a subset of T cells and assembled into a functional TCR complex. The modified T cells were activated with anti-idiotypic antibodies or digoxin [63]. Gorman et al demonstrated that a phosphorylcholine-specific  $V_H-C_\alpha$  or  $V_H-C_\beta$  formed stable chimeric proteins in EL4 T cells. Both chimeric receptor chains associated with CD3 polypeptides in functional receptor complexes and responded to phosphorylcholine coupled to Sepharose beads. The  $V_H-C_\alpha$  chimeric chain

associates with the EL4  $\beta$  chain, while the  $V_H-C_\beta$  chimeric protein appears to form either a homodimer or a heterodimer with the native EL4  $\beta$  chain [50]. Later, Brocker et al [64] generated a chimeric sFv-TCR $\beta$  and showed functional assembly with endogenous TCR/CD3 components. This allows the incorporation of new non-MHC-restricted ligand specificities into the intact TCR/CD3 complex that can exploit the full range of biological activities of the endogenous TCR signaling machinery.

#### *4.1.2.2. Directly endowing signal domains with antigen-binding domain*

The signaling domain delivers the signals for the activation of the designer T cells. Several signaling molecules that can deliver activation signals to T cells have been tested, among them Fc $\epsilon$ RI  $\gamma$  chain and CD3  $\epsilon$ ,  $\gamma$ ,  $\delta$ , and  $\zeta$ , as separate molecules and in complex. Of the CD3 chains, only  $\zeta$ , the limiting chain in the complex, can be expressed alone on cell surfaces independent of other chains in the complex. All these molecules contain immune tyrosine activation motifs (ITAM) [65, 66], which upon phosphorylation serve as docking sites for other signal transducing molecules for T cell activation [67].

##### *4.1.2.2.1. CD3 chains*

After antigen recognition occurs by the  $\alpha\beta$  chains of the TCR, the signal is transmitted via the nonpolymorphic chains of CD3 to the intracellular signaling machinery [68].

CD3 $\epsilon$  has a long history as the principal target for antibody-mediated T cell activation [69] and for redirected killing via bifunctional antibodies [70]. Nolan et al constructed anti-CEA sFv- $\epsilon$  and Fab- $\epsilon$  chimeric receptors. Such IgTCR-modified T cells showed

specific binding and activation, as demonstrated by IL-2 production on contact with immobilized CEA (Fab- $\epsilon$ , Fab- $\zeta$ ) and on CEA<sup>+</sup> tumor cells (Fab- $\epsilon$ ) [44].

The CD3 $\zeta$  chain is a nonglycosylated membrane protein that forms disulfide-linked homodimers as part of the CD3 complex. Each  $\zeta$  chain contains 3 ITAMs and it plays a central role in the transduction of signals into the cells for the T cell activation. Several experiments showed that the intracellular portion of the CD3 $\zeta$  chain is sufficient to induce activating signals after cross-linking of attached artificial extracellular domains [60, 71, 72]. Eshhar et al constructed chimeric genes by linking the sFv derived from an anti-TNP antibody with the CD3 $\zeta$  chain. This chimeric gene was expressed as a functional surface receptor in a cytolytic T-cell hybridoma, and triggered IL-2 secretion upon encountering antigen and mediated non-MHC-restricted hapten-specific target cell lysis [55]. Brocker et al later confirmed this strategy in a separate experiment [56]. Nolan et al showed high surface expression of sFv- $\zeta$  that showed normal assembly with endogenous  $\zeta$  into (sFv- $\zeta$ )( $\zeta$ ) heterodimers as well as (sFv- $\zeta$ )<sub>2</sub> and  $\zeta$ <sub>2</sub> homodimers [44].

#### 4.1.2.2.2. *Fc $\epsilon$ RI $\gamma$ chain*

The  $\gamma$  chain is the signal transducing subunit both of the high affinity IgE receptor (Fc $\epsilon$ RI) of mast cells and basophils, and of the low affinity receptor for IgG (Fc $\epsilon$ RIII), expressed primarily by macrophages and NK cells [73]. The  $\gamma$  chain is very similar in structure and function to the  $\zeta$  chain in the CD3 complex and in fact can successfully replace the  $\zeta$  chain in the CD3 complex in  $\zeta$ -deficient T cells [74]. Chimeric receptors containing the signaling domain of the  $\gamma$  chain were initially designed for mediating

specific targeting of NK cells, but then were subsequently found to effectively transmit stimulation signals in T cells as well [55, 75].

#### *4.1.2.2.3. Other signaling molecules*

Many tumor-bearing patients have been reported to have defective TCR-mediated signaling events and therefore to exhibit impaired immune response [76]. To overcome this limitation, Fitzer-Attas et al developed a new configuration of chimeric receptor in which they used the cytosolic signaling domains of molecules that signal downstream of TCR such as the protein tyrosine kinase (PTK). By connecting one of the PTK family members, Syk, through a transmembrane stretch to a hinge spacer and the sFv domain, they constructed a chimeric sFv-Syk receptor. A cytotoxic T cell hybridoma expressing this chimeric receptor was efficiently stimulated to produce IL-2 upon interaction with APC and specifically lysed appropriate target cells in a non-MHC-restricted manner [77, 78].

While different signaling molecules have been used for constructing the chimeric receptors, among them the CD3  $\zeta$  chain has been the most potent signal transduction molecule when expressed in isolation. It is reported that CD3  $\zeta$  chain was 300% more potent than the CD3  $\epsilon$  and Fc $\epsilon$ RI  $\gamma$  chain, both by IL-2 secretion and cytotoxicity [60, 79-81]. On the other hand, the native  $\zeta$  and  $\epsilon$  chains, as well as their chimeric constructs, function in T cells in the context of the full CD3 complex consisting of 10 ITAMs, in which the signaling differences between the isolated CD3  $\epsilon$  and  $\zeta$  chains disappeared [44].

#### *4.1.3. Spacer or hinge domain*

An extracellular spacer or hinge region between the antigen binding domain and the transmembrane and signaling domains has been applied to extend the distance of the antigen binding domain from the cell membrane and to provide flexibility to the antigen binding domain in its interaction with cognate antigen. A hinge was first shown to be important with CD3 $\zeta$  chain, which has a minimal extracellular domain. The presence of hinge markedly improved expression, ligand binding and signaling activity of the chimeric receptors [82, 83]. The CH2/3 constant domain of human IgG [84], the C<sub>H</sub>1 constant domain of Fab [44] and the extracellular domains of CD8 and CD7 have been used for this purpose [85]. Ren-Heidenreich et al found that T cells transduced with the chimeric receptor with a CD8 $\alpha$  hinge displayed specific lytic activity that was twofold greater than that of chimeric receptor without the hinge and also produced significantly more cytokines [86]. On the other hand, the MOv18 sFv- $\gamma$  chimera functions and expresses well without an intervening hinge spacer (Huw, personal communication).

The critical nature of this distance effect was further suggested in studies by Nolan et al [44]. The CD3 $\epsilon$  chain was coupled with an sFv and a Fab, whereas CD3 $\zeta$  was coupled with Fab or with sFv with an intervening CD8 $\alpha$  hinge (Figure 5). It was thought that the C<sub>H</sub>1-C<sub>L</sub> domain of the Fab would provide the needing spacing of the Ag-binding domain (Fv) above the membrane with the CD3 $\zeta$  signaling chain, but that the Ig-like extracellular domain of CD3 $\epsilon$  would provide this spacer function to allow efficient targeting with sFv when directly conjugated. While all four constructs activated equally well with

immobilized CEA antigen, the sFv- $\epsilon$  alone failed to bind CEA<sup>+</sup> tumor cells and activate. Among the constructs, the sFv- $\epsilon$  was estimated from molecular models to have the shortest projection from the membrane (47Å versus 65Å for Fab- $\zeta$ , the second shortest) (K. Johnson and R. P. Junghans, unpublished analyses). The antigen epitope on CEA is in the second domain of seven from the membrane. The importance of adequate intracellular distance due to electrorepulsion between negatively charged cellular membranes has been stated [87] and achieving this distance with or without spacers may be different with different antigen-chimeric receptor pairs.

#### *4.2. Effector cell types*

The basic principle of the chimeric receptor strategy for adoptive immunotherapy is to graft effector cells with neo-antigen specificity and then to infuse these back into patients to eradicate the antigen-expressing target cells. The most potent candidate effector cells are autologous peripheral blood T lymphocytes stimulated by anti-CD3 antibody alone or in combination with anti-CD28. Hwu et al developed another system by using TILs, which are tumor-reactive T cells isolated from tumor sites [41, 88]. Cytotoxic T cell lines such as the human TALL-104 T cell line are a further example, which has been approved for clinical trial [89] and may also be a good candidate to be modified with the chimeric receptor and used in an analogous manner.

Apart from T cells, chimeric receptors may also be used to redirect other cell types. NK cells are known to have an inherent capacity to target many types of tumor cells, but lack adequate specificity for successful in vivo therapy. Bach et al reported that NK cells

transfected with chimeric receptor genes can specifically lyse tumor cells [90]. Wang et al reported that recipients of bone marrow cells transduced with chimeric receptor genes exhibited significant antitumor activity in vivo. In vivo depletion of T cells in the reconstituted mice did not affect antitumor activity, suggesting that other non-T immune cells expressing the chimeric receptor gene may play an important role in tumor rejection [91]. Roberts et al reported specific lysis by neutrophils expressing chimeric receptors [80]. It is anticipated that chimeric receptors would also function in activating monocytes, macrophage, and other cell types [92].

For some applications, chimeric receptor modification of hematopoietic stem cells (HSC) may be preferable to modification of terminally differentiated T cells. The self-renewing nature and transplantability of hematopoiesis would allow the permanent generation of a stable population of tumor-specific effector cells. Hege et al modified murine HSC with a human immunodeficiency virus (HIV) envelope-specific chimeric receptor consisting of the extracellular domain of human CD4 linked to the  $\zeta$  chain of the T cell receptor (CD4- $\zeta$ ). After transplantation into immunodeficient SCID mice, sustained high level expression of CD4- $\zeta$  was observed in circulating myeloid and natural killer cells. CD4- $\zeta$ -transplanted mice were protected from challenge with a lethal dose of a disseminated human leukemia cell line expressing HIV envelope [93].

#### *4.3. Monitoring chimeric receptor expression and enriching modified cells*

Antibodies that can recognize the chimeric receptors expressed on the modified cells are very useful tools for monitoring the chimeric receptor expression, for enriching the



receptor expressing cells by panning or cell sorting, and for testing the function of the chimeric receptor. The chimeric receptor's expression can be detected by anti-idiotypic antibodies for the sFv (Figure 6) [24], antibodies recognizing the spacer region such as the CH2/CH3 region of human IgG, or antibodies against a tag peptide inserted into the chimeric receptors. Soluble ligand/antigen may be similarly applied for panning or, when appropriable conjugated, for detection of expression

#### *4.4. Function of designer T cells*

##### *4.4.1. Expression*

For functional expression on the T cell surface, the chimeric molecules when appropriately expressed will assemble as part of a functional receptor complex, as supported by several lines of evidence [50, 94]. In this manner, the chimeric receptors that have successfully assembled will transduce signals to the modified T cells in the manner of the parent receptor.

##### *4.4.2. Binding*

The formation of conjugates between the effector T cells and their target cells is a prerequisite for T-cell dependent activation and cytotoxicity. Upon contact with the target cells, the chimeric receptor-modified T cells can bind tightly with the target cells as shown in Figure 7 by Yun et al [51].

##### *4.4.3. Activation*

Once T cells bind specifically with the target cells by TCR, the T cells will be activated to secrete cytokines to regulate the immune reaction. With co-culturing of chimeric receptor modified T cells with their target cells, increased production of several cytokines have been recorded such as IL-2 (Figure 8) [44, 56], IL-3 [56], IFN- $\gamma$  [95, 96] and GM-CSF [75]. It is noted, however, that the IL-2 assays are typically in the presence of phorbol ester (PMA) that bypasses the need for co-stimulatory signals of normal IL-2 secretion [97, 98]. As such, this assay is a sensitive measure of TCR activation but not of authentic IL-2 secretion.

#### *4.4.4. Cytotoxicity*

The cytolytic function of chimeric receptor-modified T cells is the most important property for the deployment of T cells in adoptive immunotherapy. The engineered T cells lyse their target cells in chimeric receptor-specificity dependent and MHC non-dependent fashion [55]. In addition, Weijtens et al [99], Nolan et al [44] and Yun et al [51] found that the engineered T cells could recycle their lytic activity by cycling between target cells, with multiple killing events per T cell (Figure 9).

#### *4.4.5. In vivo tumor suppression*

Using in vivo model systems, Moritz et al demonstrated that the growth of ErbB2-transformed cells in athymic nude mice was retarded by adoptively transferred cytotoxic T lymphocytes (CTLs) modified with a chimeric receptor specific for ErbB2 receptor-expressing tumor cells (Figure 10). They further demonstrated that only T cells expressing the chimeric receptor gene homed to the ErbB2-expressing tumors; nontransduced parental T cells did not [100]. Hwu et al reported that lymphocytes

transfected with a chimeric receptor of anti-folate binding protein specificity, were shown to eliminate experimental tumors in mice (Figure 11) [101]. Altenschmidt et al treated tumor bearing mice with transduced T cells and found that the adoptively transferred sFv(FRP5)- $\zeta$ -expressing T cells caused total regression of ErbB-2-expressing tumors [102]. In a recent study, Darcy et al reported that in vivo specific tumor cell cytotoxicity was mediated by gene-modified CD8<sup>+</sup> T cells. Furthermore, using gene-targeted and chimeric receptor-transduced donor CTL, perforin and IFN- $\gamma$  were demonstrated to be critical for the eradication of colon carcinoma in mice [96].

#### *4.5. Tumor antigens as designer T cell targets*

It has been controversial for decades whether tumor “specific” antigens exist. Several tumor antigens that can induce T-cell or humoral immunity have been cloned from different tumor models [103]. Those antigens are either mutated proteins or they may be normal self-proteins that are over-expressed in tumor. How to manipulate effective T cell immunity against these tumor antigens has been a major objective of recent tumor immunology strategies. Retargeting T cells against tumor antigens by genetically engineered T cells with chimeric receptors is one such approach. However, the T cells may also be redirected at proteins that are expressed in normal tissues when treating metastatic tumors (e.g., prostate membrane specific antigen on prostate).

In this chimeric receptor strategy, it is evident that the targeted antigen must be membrane-bound, expressed on the surface of tumor cells. Using this technology,

redirected T cells have been developed against a large number of predefined tumor targets as listed in Table 1.

#### *4.6. Clinical trials*

To date, patient experience with designer T cells has been limited, and most studies are still unpublished. Table 2 lists trials that are current or soon to be initiated. A CD4- $\zeta$  chimera [127] was applied in HIV with doses to  $3 \times 10^{10}$  cells in 24 patients, 11 with IL-2 infusion  $\times$  1wk, with good tolerance and decreased viral load in the mucosal compartment [128]. Studies of ovarian carcinoma with an anti-MOv18 chimera [101] applied 18 doses to a maximum of  $5 \times 10^{10}$  cells + IL-2 in eight patients without toxicity or clinical response (P. Hwu, personal communication). An anti-TAG72 IgTCR was applied in colorectal cancer, with dose to  $10^{10}$  cells in ten patients, was well tolerated without clinical responses [129] (K. Hege, personal communication). The initial report indicated responses after treatment by decline of TAG72 in several patients. However, this was lately shown to be due to an anti-idiotypic antibody response in patient sera that interfered with an ELISA assay to give a false impression of decreased TAG72 (K. Hege, personal communication). Our own on-going Phase I tests applied 24 doses of anti-CEA IgTCR up to  $10^{11}$  cells in seven patients, with adequate tolerance and minor responses in two patients [130]. In general, treatment with IgTCR-modified T cells has been well tolerated with suggestions of efficacy, but until now without durable, meaningful responses. The outcome of these several on-going and pending studies will be awaited with interest, and will undoubtedly yield crucial information to guide future modifications and improvements in the best traditions of translational research. Some of

these needed improvements are already becoming evident from the presently available phase I data, as described in the following section.

## **5. Conclusions and Future Directions**

The challenge for using designer T cells for adoptive immunotherapy is how to enhance and sustain the survival and expansion of the modified T cells in the tumor sites.

Currently, the chimeric receptor modified T cells are ex vivo activated T cells. One of the limitations for this kind of adoptive immunotherapy has been that TCR ligation by the activated T cells usually leads to activation-induced cell death (AICD) [106, 131].

Although the modified T cells execute their effector functions to kill the target cells, they will ultimately undergo AICD after contacting the target cells. How to prevent the modified T cells from AICD when they conjugate with their targets is a key to the next generation of designer T cells to make this treatment more successful. The knowledge obtained from current research developments in the processes of T cell activation and apoptosis will play a crucial role in directing the development of future modifications of this new type of therapy.

According to the generally accepted two-signal requirement model for T-cell activation, the functional outcome of TCR ligation varies, depending on the presence or absence of additional costimulatory signals delivered to the T cell via APC [97, 98]. Antigenic stimulation can lead either to a productive immune response characterized by proliferation, differentiation, clonal expansion and effector function or, in the absence of appropriate costimulation, to a state of long-lasting antigen-specific unresponsiveness

termed anergy, or to cell deletion [132]. CD28 is one of the crucial receptors on the T cell surface to receive costimulatory signals delivered by B7-1 and B7-2 from the APC, with impact on multiple aspects of T-cell physiology. CD28 ligation enhances the magnitude and duration of T-cell responses; induces the anti-apoptotic gene Bcl-X<sub>L</sub>; increases cytokine secretion, particularly IL-2; enhances cell adhesion; facilitates reorganization of the T-cell plasma membrane upon binding to an APC; prevents energy induction; and supports germinal center formations [133].

Several groups have explored the possibility to incorporate a costimulation signal into the IgTCR modified T cells [25, 106, 112, 134, 135]. Alvarez-Vallina et al generated T cells that express both sFv-CD3 $\zeta$  and sFv-CD28 and they demonstrated that antigen-specific co-stimulatory signals could synergize with signals mediated through chimeric CD3 $\zeta$  chains to secrete maximal levels of IL-2 [134]. Beecham et al showed that in addition to IgTCR signals, CD28 costimulation is required to induce expansions of previously activated peripheral blood mononuclear cell-derived T cells. Signals from IgTCR alone could induce transient cell division, but they could not induce the prolonged polyclonal expansions that are characteristic of native immune responses. CD28 costimulation also suppressed the deletion of tumor-reactive subclones by AICD [106]. Eshhar et al modified human PBL with a tripartite construct consisting of a sFv for TNP linked to part of the extracellular domain and the membrane spanning regions of the CD28 and joined at its cytoplasmic terminus to the  $\gamma$  signaling chain. Upon stimulation with immobilized TNP, the chimeric receptor-expressing T cells produce IL-2, underwent specific proliferation in the absence of exogenous IL-2, and effectively lysed target TNP<sup>+</sup> cells.

However, in the presence of antigen excess, AICD of the modified T cells was not prevented by the presence of CD28 in the signal receptor [25]. Whereas other signals clearly will be important in their sustained growth, the ultimate configuration(s) of designer T cells for therapeutic success is still to be determined.

Genetic engineering of T cells with chimeric receptors attempts to combine the specificity of antibodies with the efficient cytotoxic effector properties of T cells. This and other areas of research will shape future generations of designer T cells in the evolving application of these new technologies. There is reason for optimism that this path will lead to important therapeutic impact in many cancers for which options are presently woefully lacking. The next 5-10 years are likely to produce dramatic gains in immunotherapeutic modalities generally, and in targeted cellular strategies specifically.

## Figure Legends

**Figure 1.** Retroviral vector action. A packaging cell line (or helper cell line) contains separately expressed viral genes for enzyme and structural proteins that produce empty virions. The gene of interest (“transgene”) is cloned into a retroviral vector DNA which is transferred into the packaging cell line, creating a vector producer cell (VPC). The RNA transcripts from the vector DNA possess a packaging signal ( $\psi^+$ ) that is recognized by the capsid proteins and causes RNA to be packaged thus creating complete viral particles. These viral supernatants are used to infect the T cell, where the viral RNA is copied to DNA by the virally encoded Reverse Transcriptase. The viral DNA is then integrated into the T cell genome for stable expression of the transgene. (Modified from reference [18], with permission).

**Figure 2.** Retroviral vectors used to transduce TILs with genes for neomycin phosphotransferase (Neo<sup>R</sup>) and TNF. Arrow indicates gene transcription from LTR promoter. SV, SV40 virus promoter; TM, transmembrane. (From reference [29], with permission).

**Figure 3.** Structure of an IgTCR. The T cell receptor/CD3 complex (TCR) is comprised of six proteins:  $\alpha$ ,  $\beta$ ,  $\gamma$ ,  $\delta$ ,  $\epsilon$  and  $\zeta$ . The structure of the  $\alpha\beta$  receptor chains is analogous to the Fab portion of an antibody (Ab) with variable (V) and constant (C) domains.  $\gamma$  and  $\epsilon$  also have Ig-like extracellular domains. Boxes in the cytoplasmic domains represent signaling motifs in all chains except  $\alpha$  and  $\beta$ . Antibody V regions are engineered to



create an sFv and then linked to the signaling portion of  $\zeta$ , in this IgTCR representation, with an intervening spacer derived from the hinge portion of CD8 $\alpha$ . (From reference [44] with permission).

**Figure 4.** Scheme for preparation of designer T cells for patient treatment. Peripheral blood mononuclear cells are harvested from the patient, and T cells are activated by anti-CD3 antibody treatment for 2-3 days. Subsequently, T cells are infected with IgTCR retroviral supernatant to express the IgTCR transgene. Autologous chimeric T cells are expanded ex vivo and infused back into the patient, who is then observed for anti-tumor effect.

**Figure 5.** Representation of the IgTCR molecules. sFv-CD8 $\alpha$  hinge- $\zeta$ , Fab- $\zeta$ , sFv- $\epsilon$  and Fab- $\epsilon$  are shown in the context of complete TCR complexes. The distance of the antigen-binding domain from the cell membrane is different for each four constructs. (From reference [44], with permission).

**Figure 6.** Detecting IgTCR expression. Activated human T cells were infected with anti-CEA IgTCR vector, stained with either PE-labeled anti-idiotypic antibody (solid lines) or with negative control antibody (dotted lines). (From reference [24], with permission).

**Figure 7.** Cell conjugation of IgTCR<sup>+</sup> T cells with GD3<sup>+</sup> melanoma cells. After co-incubation of nonadherent T cell effectors (round shaped cells) and adherent tumor cell targets (spindle-shape) on plates, unbound T cells were removed by washing. (A)

Unmodified T cells were nearly completely washed away, showing only the tumor cells left in plate. (B) IgTCR+ modified T cells bound tightly to GD3+ melanoma cells (From reference [51], with permission).

**Figure 8.** Anti-CEA designer T cells secrete IL-2 on binding CEA+ tumor cells. Jurkat IgTCR+ transduced cell line was stimulated with various stimuli and the supernatants were harvested and tested for IL-2 concentrations. Stimulators were: BSA; CEA; CEA-negative colon cancer cell line (MIP-101); CEA-positive colon cancer cell line (MIP-CEA). IL-2 levels were standardized to OKT3-stimulated secretion. (From reference [44], with permission).

**Figure 9.** Cytotoxicity of IgTCR-modified normal human T cells against antigen-expressing targets. MIP-101 (CEA-) and MIP-CEA (CEA+) tumor cells were seeded at  $10^5$  cells per well, to which IgTCR-modified CD8+ CTLs were added at an E:T ratio of 0.15:1, and counted daily for viable tumor cells. (From reference [44], with permission).

**Figure 10.** Cytotoxicity and antitumor activity of sFv/ $\zeta$ -transduced CTLs against human ERBB2-expressing target cells. (A) In vitro 8 hr-cytotoxicity assay (LDH release). sFv/ $\zeta$ -transduced CTL lysed ErbB2-transfected NIH 3T3 fibroblasts (■) or ErbB2-transfected HC11 breast epithelial cells (●) at varying effector:target (E:T) ratios. Control, unmodified CTLs were unable to lyse either cell line (○, □). (B) In vivo co-administration of transduced CTLs and tumor cells suppressed tumor formation for up to 8 days. ErbB2+ tumor cells were mixed with sFv/ $\zeta$ -transduced CTLs (■) or nontransduced CTLs

(□) at a ratio of 10:1 and injected subcutaneously. Tumor cells without CTLs (▲) are shown as a control. (C) In vivo antitumor activity with delayed injection of sFv/ζ-transduced CTLs. Balb/c mice were inoculated subcutaneously with ErbB2+ tumor cells. On days 4 and 5, when tumors were palpable, nontransduced CTLs (□) and transduced CTLs (■) were injected intravenously through the tail vein. IL-2 was administered intraperitoneally on days 4, 5 and 6. Tumor cells without (▲) and with (Δ) IL-2 are shown as controls. The transduced CTLs delayed growth of tumor cells, but without curing the mice. (From reference [100], with permission).

**Figure 11.** In vivo activity of MOv-γ-transduced TIL against human ovarian carcinoma (IGROV) cells over-expressing folate binding protein (FBP). Three days after i.p. injection of nude mice with IGROV cells, mice were treated with saline solution (HBSS), TILs that were nontransduced (NV-TIL), transduced with the anti-FBP chimeric MOv-γ receptor (MOv-TIL) or transduced with control irrelevant chimeric receptor (TNP-TIL). Mice treated with MOv-TIL had significantly increased survival ( $P < 0.002$ ) compared to other groups. (From reference [101], with permission).

## References

- [1] Burnett FM. The concept of immunological surveillance. *Progr Exp Tumor Res* 1970;13:1-27.
- [2] Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. *Adv Immunol* 1991;49:281-355.
- [3] Rosenberg SA, Lotze MT, Muul LM et al. Observations on the systemic administration of autologous lymphokine- activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985;313:1485-92.
- [4] Rosenberg SA, Lotze MT, Yang JC et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. *J Natl Cancer Inst* 1993;85:622-32.
- [5] Rosenberg SA. The development of new immunotherapies for the treatment of cancer using interleukin-2. A review. *Ann Surg* 1988;208:121-35.
- [6] Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. *J Immunol* 1985;135:4273-80.
- [7] Ettinghausen SE, Lipford EH 3rd, Mule JJ, Rosenberg SA. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells. *J Immunol* 1985;135:3623-35.
- [8] Van den Eynde BJ, Boon T. Tumor antigens recognized by T lymphocytes. *Int J Clin*

Lab Res 1997;27:81-6.

[9] Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987;79:1067-75.

[10] Fisher B, Packard BS, Read EJ et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 1989;7:250-61.

[11] Griffith KD, Read EJ, Carrasquillo JA et al. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989;81:1709-17.

[12] Pockaj BA, Sherry RM, Wei JP et al. Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 1994;73:1731-7.

[13] Economou JS, Belldegrun AS, Glaspy J et al. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J Clin Invest 1996;97:515-21.

[14] Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994;86:1159-66.

[15] Sykulev Y, Cohen RJ, Eisen HN. The law of mass action governs antigen-stimulated cytolytic activity of CD8+ cytotoxic T lymphocytes. Proc Natl Acad Sci U S A 1995;92:11990-2.

[16] Valitutti S, Lanzavecchia A. Serial triggering of TCRs: a basis for the sensitivity and

specificity of antigen recognition. *Immunol Today* 1997;18:299-304.

[17] Hwu P. Genetic therapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. *Cancer: Principles & Practice of Oncology*. Philadelphia: Lippincott Williams & Wilkins, 2001; 3161-80.

[18] Vile RG, Russell SJ. Retroviruses as vectors. *Br Med Bull* 1995;51:12-30.

[19] Bunnell BA, Muul LM, Donahue RE, Blaese RM, Morgan RA. High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. *Proc Natl Acad Sci U S A* 1995;92:7739-43.

[20] Lam JS, Reeves ME, Cowherd R, Rosenberg SA, Hwu P. Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope. *Hum Gene Ther* 1996;7:1415-22.

[21] Pollok KE, van der Loo JC, Cooper RJ, Kennedy L, Williams DA. Costimulation of transduced T lymphocytes via T cell receptor-CD3 complex and CD28 leads to increased transcription of integrated retrovirus. *Hum Gene Ther* 1999;10:2221-36.

[22] Pollok KE, Hanenberg H, Noblitt TW et al. High-efficiency gene transfer into normal and adenosine deaminase- deficient T lymphocytes is mediated by transduction on recombinant fibronectin fragments. *J Virol* 1998;72:4882-92.

[23] Dardalhon V, Jaleco S, Rebouissou C et al. Highly efficient gene transfer in naive human T cells with a murine leukemia virus-based vector. *Blood* 2000;96:885-93.

[24] Beecham EJ, Ortiz-Pujols S, Junghans RP. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor. *J Immunother* 2000;23:332-43.

[25] Eshhar Z, Waks T, Bendavid A, Schindler DG. Functional expression of chimeric

receptor genes in human T cells. *J Immunol Methods* 2001;248:67-76.

[26] Jensen MC, Clarke P, Tan G et al. Human T lymphocyte genetic modification with naked DNA. *Mol Ther* 2000;1:49-55.

[27] Rosenberg SA, Aebersold P, Cornetta K et al. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. *N Engl J Med* 1990;323:570-8.

[28] Kasid A, Morecki S, Aebersold P et al. Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. *Proc Natl Acad Sci U S A* 1990;87:473-7.

[29] Rosenberg SA, Anderson WF, Blaese M et al. The development of gene therapy for the treatment of cancer. *Ann Surg* 1993;218:455-63; discussion 463-4.

[30] Favrot MC, Philip T. Treatment of patients with advanced cancer using tumor infiltrating lymphocytes transduced with the gene of resistance to neomycin. *Hum Gene Ther* 1992;3:533-42.

[31] Riddell SR, Greenberg PD, Overell RW et al. Phase I study of cellular adoptive immunotherapy using genetically modified CD8+ HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. *Hum Gene Ther* 1992;3:319-38.

[32] Lotze MT. T-cell growth factors and the treatment of patients with cancer. *Clin Immunol Immunopathol* 1992;62:S47-54.

[33] Yamada G, Kitamura Y, Sonoda H et al. Retroviral expression of the human IL-2

gene in a murine T cell line results in cell growth autonomy and tumorigenicity. *EMBO J* 1987;6:2705-9.

[34] Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. *J Exp Med* 1989;169:13-25.

[35] Treisman J, Hwu P, Minamoto S et al. Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. *Blood* 1995;85:139-45.

[36] Minamoto S, Treisman J, Hankins WD, Sugamura K, Rosenberg SA. Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors. *Blood* 1995;86:2281-7.

[37] Evans LS, Witte PR, Feldhaus AL et al. Expression of chimeric granulocyte-macrophage colony-stimulating factor/interleukin 2 receptors in human cytotoxic T lymphocyte clones results in granulocyte-macrophage colony-stimulating factor-dependent growth. *Hum Gene Ther* 1999;10:1941-51.

[38] Creasey AA, Reynolds MT, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. *Cancer Res* 1986;46:5687-90.

[39] Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. *J Immunol* 1987;138:963-74.

[40] Hwu P, Yannelli J, Kriegler M et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the



gene therapy of cancer in humans. *J Immunol* 1993;150:4104-15.

[41] Hwu P, Rosenberg SA. The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials. *Cancer Detect Prev* 1994;18:43-50.

[42] Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. *Cell* 1990;63:251-8.

[43] Yee C, Riddell SR, Greenberg PD. Prospects for adoptive T cell therapy. *Curr Opin Immunol* 1997;9:702-8.

[44] Nolan KF, Yun CO, Akamatsu Y et al. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. *Clin Cancer Res* 1999;5:3928-41.

[45] Punt JA, Roberts JL, Kearse KP, Singer A. Stoichiometry of the T cell antigen receptor (TCR) complex: each TCR/CD3 complex contains one TCR alpha, one TCR beta, and two CD3 epsilon chains. *J Exp Med* 1994;180:587-93.

[46] Chan AC, Irving BA, Weiss A. New insights into T-cell antigen receptor structure and signal transduction. *Curr Opin Immunol* 1992;4:246-51.

[47] Bolhuis RL, Gratama JW. Genetic re-targeting of T lymphocyte specificity. *Gene Ther* 1998;5:1153-5.

[48] Kuwana Y, Asakura Y, Utsunomiya N et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. *Biochem Biophys Res Commun* 1987;149:960-8.

[49] Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci U S*

A 1989;86:10024-8.

[50] Gorman J, Gomez SM, Segesman KD, Hunkapiller T, Laug WE, Hood L.

Chimeric immunoglobulin-T cell receptor proteins form functional receptors:

implications for T cell receptor complex formation and activation. *Cell* 1990;60:929-39.

[51] Yun CO, Nolan KF, Beecham EJ, Reisfeld RA, Junghans RP. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. *Neoplasia* 2000;2:449-59.

[52] Brinkmann U, Reiter Y, Jung SH, Lee B, Pastan I. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. *Proc Natl Acad Sci U S A* 1993;90:7538-42.

[53] Huston JS, Levinson D, Mudgett-Hunter M et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proc Natl Acad Sci U S A* 1988;85:5879-83.

[54] Bird RE, Hardman KD, Jacobson JW et al. Single-chain antigen-binding proteins. *Science* 1988;242:423-6.

[55] Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci U S A* 1993;90:720-4.

[56] Brocker T, Peter A, Traunecker A, Karjalainen K. New simplified molecular design for functional T cell receptor. *Eur J Immunol* 1993;23:1435-9.

[57] Akamatsu Y, Murphy JC, Nolan KF et al. A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells. *Clin*

Cancer Res 1998;4:2825-32.

[58] Chaudhary VK, Queen C, Junghans RP, Waldmann TA, FitzGerald DJ, Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to *Pseudomonas* exotoxin. *Nature* 1989;339:394-7.

[59] Willemsen RA, Weijtens ME, Ronteltap C et al. Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. *Gene Ther* 2000;7:1369-77.

[60] Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. *Cell* 1991;64:1037-46.

[61] Altenschmidt U, Kahl R, Moritz D et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. *Clin Cancer Res* 1996;2:1001-8.

[62] Kahlon SK, Jensen MC. Redirecting T lymphocyte antigen specificity via engineered zetamine immunoreceptors: development of a prototype construct specific for the tumor-restricted IL-2alpha receptor. Abstract presented in the Fourth Annual Meeting of the American Society of Gene Therapy 2001.

[63] Becker ML, Near R, Mudgett-Hunter M et al. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. *Cell* 1989;58:911-21.

[64] Brocker T, Riedinger M, Karjalainen K. Redirecting the complete T cell receptor/CD3 signaling machinery towards native antigen via modified T cell receptor. *Eur J Immunol* 1996;26:1770-4.

[65] Isakov N. ITIMs and ITAMs. The Yin and Yang of antigen and Fc receptor-linked

signaling machinery. *Immunol Res* 1997;16:85-100.

[66] Isakov N. Immunoreceptor tyrosine-based activation motif (ITAM), a unique module linking antigen and Fc receptors to their signaling cascades. *J Leukoc Biol* 1997;61:6-16.

[67] Cantrell D. T cell antigen receptor signal transduction pathways. *Annu Rev Immunol* 1996;14:259-74.

[68] Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. *Cell* 1994;76:263-74.

[69] Transy C, Moingeon PE, Marshall B, Stebbins C, Reinherz EL. Most anti-human CD3 monoclonal antibodies are directed to the CD3 epsilon subunit. *Eur J Immunol* 1989;19:947-50.

[70] Renner C, Pfreundschuh M. Tumor therapy by immune recruitment with bispecific antibodies. *Immunol Rev* 1995;145:179-209.

[71] Irving BA, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. *Cell* 1991;64:891-901.

[72] Wegener AM, Letourneur F, Hoeveler A, Brocker T, Luton F, Malissen B. The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. *Cell* 1992;68:83-95.

[73] Ravetch JV, Kinet JP. Fc receptors. *Annu Rev Immunol* 1991;9:457-92.

[74] Liu CP, Lin WJ, Huang M, Kappler JW, Marrack P. Development and function of T cells in T cell antigen receptor/CD3 zeta knockout mice reconstituted with Fc epsilon RI gamma. *Proc Natl Acad Sci U S A* 1997;94:616-21.

- [75] Hwu P, Shafer GE, Treisman J et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. *J Exp Med* 1993;178:361-6.
- [76] Zier K, Gansbacher B, Salvadori S. Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapy. *Immunol Today* 1996;17:39-45.
- [77] Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Direct T cell activation by chimeric single chain Fv-Syk promotes Syk- Cbl association and Cbl phosphorylation. *J Biol Chem* 1997;272:8551-7.
- [78] Fitzer-Attas CJ, Schindler DG, Waks T, Eshhar Z. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. *J Immunol* 1998;160:145-54.
- [79] Letourneur F, Klausner RD. T-cell and basophil activation through the cytoplasmic tail of T-cell- receptor zeta family proteins. *Proc Natl Acad Sci U S A* 1991;88:8905-9.
- [80] Roberts MR, Cooke KS, Tran AC et al. Antigen-specific cytotoxicity by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. *J Immunol* 1998;161:375-84.
- [81] Haynes NM, Snook MB, Trapani JA et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. *J Immunol* 2001;166:182-7.
- [82] Moritz D, Groner B. A spacer region between the single chain antibody- and the CD3 zeta- chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. *Gene Ther* 1995;2:539-46.

- [83] Kershaw MH, Darcy PK, Hulett MD, Hogarth PM, Trapani JA, Smyth MJ. Redirected cytotoxic effector function. Requirements for expression of chimeric single chain high affinity immunoglobulin e receptors. *J Biol Chem* 1996;271:21214-20.
- [84] Hombach A, Sircar R, Heuser C et al. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains. *Int J Mol Med* 1998;2:99-103.
- [85] Patel SD, Moskalenko M, Smith D, Maske B, Finer MH, McArthur JG. Impact of chimeric immune receptor extracellular protein domains on T cell function. *Gene Ther* 1999;6:412-9.
- [86] Ren-Heidenreich L, Hayman GT, Trevor KT. Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors. *Hum Gene Ther* 2000;11:9-19.
- [87] To be provided.
- [88] Hwu P, Rosenberg SA. The use of gene-modified tumor-infiltrating lymphocytes for cancer therapy. *Ann N Y Acad Sci* 1994;716:188-97; discussion 197-203.
- [89] Visonneau S, Cesano A, Porter DL et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. *Clin Cancer Res* 2000;6:1744-54.
- [90] Bach NL, Eshhar Z. Specific lysis of tumor cells by a natural killer like cell line transfected with chimeric receptor genes. *Tumor Target* 1995;1:203.
- [91] Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. *Nat Med* 1998;4:168-72.

- [92] Geiger TL, Jyothi MD. Development and application of receptor-modified T lymphocytes for adoptive immunotherapy. *Transfus Med Rev* 2001;15:21-34.
- [93] Hege KM, Cooke KS, Finer MH, Zsebo KM, Roberts MR. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. *J Exp Med* 1996;184:2261-9.
- [94] Gorochov G, Lustgarten J, Waks T, Gross G, Eshhar Z. Functional assembly of chimeric T-cell receptor chains. *Int J Cancer Suppl* 1992;7:53-7.
- [95] Hombach A, Schneider C, Sent D et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen- positive tumor cells. *Int J Cancer* 2000;88:115-20.
- [96] Darcy PK, Haynes NM, Snook MB et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. *J Immunol* 2000;164:3705-12.
- [97] Sprent J. Presidential address to the American Association of Immunologists. Stimulating naive T cells. *J Immunol* 1999;163:4629-36.
- [98] Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. *Cancer Res* 1999;59:5800-7.
- [99] Weijtens ME, Willemsen RA, Valerio D, Stam K, Bolhuis RL. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. *J Immunol* 1996;157:836-43.
- [100] Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. *Proc Natl Acad Sci U S A* 1994;91:4318-22.

- [101] Hwu P, Yang JC, Cowherd R et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. *Cancer Res* 1995;55:3369-73.
- [102] Altenschmidt U, Klundt E, Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. *J Immunol* 1997;159:5509-15.
- [103] Ockert D, Schmitz M, Hampl M, Rieber EP. Advances in cancer immunotherapy. *Immunol Today* 1999;20:63-5.
- [104] Kershaw MH, Westwood JA, Zhu Z, Witte L, Libutti SK, Hwu P. Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature. *Hum Gene Ther* 2000;11:2445-52.
- [105] Darcy PK, Kershaw MH, Trapani JA, Smyth MJ. Expression in cytotoxic T lymphocytes of a single-chain anti- carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma. *Eur J Immunol* 1998;28:1663-72.
- [106] Beecham EJ, Ma Q, Ripley R, Junghans RP. Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. *J Immunother* 2000;23:631-42.
- [107] Hombach A, Koch D, Sircar R et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. *Gene Ther* 1999;6:300-4.
- [108] Kuroki M, Arakawa F, Khare PD et al. Specific targeting strategies of cancer gene therapy using a single- chain variable fragment (scFv) with a high affinity for CEA. *Anticancer Res* 2000;20:4067-71.
- [109] Jensen M, Tan G, Forman S, Wu AM, Raubitschek A. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of



CD20+ malignancy. *Biol Blood Marrow Transplant* 1998;4:75-83.

[110] Hombach A, Heuser C, Sircar R et al. An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T- cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. *Cancer Res* 1998;58:1116-9.

[111] Hombach A, Heuser C, Sircar R et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen. *J Immunother* 1999;22:473-80.

[112] Finney HM, Lawson AD, Bebbington CR, Weir AN. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. *J Immunol* 1998;161:2791-7.

[113] Hekele A, Dall P, Moritz D et al. Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera. *Int J Cancer* 1996;68:232-8.

[114] Dall P, Hekele A, Beckmann MW, Bender HG, Herrlich P, Ponta H. Efficient lysis of CD44v7/8-presenting target cells by genetically engineered cytotoxic T-lymphocytes-- a model for immunogene therapy of cervical cancer. *Gynecol Oncol* 1997;66:209-16.

[115] Daly T, Royal RE, Kershaw MH et al. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene. *Cancer Gene Ther* 2000;7:284-91.

[116] Parker LL, Do MT, Westwood JA et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. *Hum Gene Ther* 2000;11:2377-87.

[117] Weijtens ME, Willemsen RA, van Krimpen BA, Bolhuis RL. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and

accessory molecules. *Int J Cancer* 1998;77:181-7.

[118] Weijtens ME, Hart EH, Bolhuis RL. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytotoxicity and lymphokine production. *Gene Ther* 2000;7:35-42.

[119] Reinhold U, Liu L, Ludtke-Handjery HC et al. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. *J Invest Dermatol* 1999;112:744-50.

[120] Abken H, Hombach A, Heuser C, Reinhold U. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. *Recent Results Cancer Res* 2001;158:249-64.

[121] Mezzanzanica D, Canevari S, Mazzoni A et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. *Cancer Gene Ther* 1998;5:401-7.

[122] Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. *J Immunol* 1993;151:6577-82.

[123] Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. *Neoplasia* 1999;1:123-7.

[124] Ma Q, Safar M, Junghans RP. "Designer T Cells" against Prostate Specific Membrane Antigen (PSMA)-Expressing Tumors. 2001;in preparation.

[125] Hombach A, Heuser C, Sircar R et al. T cell targeting of TAG72+ tumor cells by a

chimeric receptor with antibody-like specificity for a carbohydrate epitope.

Gastroenterology 1997;113:1163-70.

[126] Patel SD, Ge Y, Moskalenko M, McArthur JG. Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions. J Immunother 2000;23:661-8.

[127] Roberts MR, Qin L, Zhang D et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994;84:2878-89.

[128] Mitsuyasu RT, Anton PA, Deeks SG et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects. Blood 2000;96:785-93.

[129] Warren RS, Fisher G.A. , Bergland EK et al. Studies of regional and systemic gene therapy with autologous CC49-Zeta modified T cells in colorectal cancer metastatic to liver. Abstract presented at the 7th International Conference on Gene Therapy of Cancer 1998.

[130] Junghans RP, Safa M, Huberman MS et al. Preclinical and phase I data of anti-CEA designer T cell therapy for cancer: a new immunotherapeutic modality. Proc Am Assoc Can Res 2000;41:543.

[131] Lenardo M, Chan KM, Hornung F et al. Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 1999;17:221-53.

[132] Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 1996;153:5-26.


- [133] Chambers CA. The expanding world of co-stimulation: the two-signal model revisited. *Trends Immunol* 2001;22:217-23.
- [134] Alvarez-Vallina L, Hawkins RE. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. *Eur J Immunol* 1996;26:2304-9.
- [135] Krause A, Guo HF, Latouche JB, Tan C, Cheung NK, Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. *J Exp Med* 1998;188:619-26.

Table 1. Tumor antigens as targets for designer T cells


Antigen	Tumor	Reference
Angiogenic endothelial cell receptor: Kinase insert domain-containing receptor (KDR)	Tumor neovasculature	[104]
Carcinoembryonic antigen (CEA)	Colorectal, breast, lung and other cancers	[24, 44, 81, 95, 96, 105-108]
CD20	B-cell lymphoma	[109]
CD30	Hodgkin's lymphoma	[110, 111]
CD33	Leukemia	[112]
CD44	Pancreatic carcinoma	[113, 114]
EGP40	Colorectal cancer	[115]
Epithelial glycoprotein 2 (EGP-2)	Many human carcinomas (breast, colon, lung, renal, pancreatic)	[86]
ErbB-3 and ErbB-4		[61]
Folate binding protein (FBP)	Ovarian carcinoma	[75, 91, 101, 101, 116]
G250	Renal cell carcinoma	[99, 117, 118]
GD3	Melanoma	[51]
High molecular weight-melanoma associated antigen (HMW-MAA)	Melanoma	[119, 120]
Lewis <sup>y</sup>	Several human carcinomas	[121]
MAGE-A1/HLA-A1	Melanoma	[59]
Neu/HER-2/ErbB-2	Adenocarcinomas	[61, 100, 102, 122]
Prostate specific membrane antigen (PSMA)	Prostate cancer	[123, 124]
TAG72	Gastrointestinal adenocarcinoma and pan-adenocarcinoma	[84, 125, 126]

Table 2. Clinical trials with chimeric receptors redirected T cells.


Date initiated	Phase	Disease	Antigen	Structure	Location	Investigator
1996	I	Ovarian cancer	FBP	sFv- $\gamma$	NCI	Hwu
1997	I	HIV	gp120	CD4- $\zeta$	Multi	Hege
1997	I	Adenocarcinoma	TAG72	sFv- $\zeta$	Stanford	Hege
1998	I	Adenocarcinoma	CEA	sFv- $\zeta$	Harvard	Junghans
2000	I	Lymphoma	CD19	sFv- $\zeta$	City of Hope	Jensen
2002 (pending)	I	Renal cell carcinoma	G250	sFv- $\zeta$	den hoed CC	Bolhuis
2002 (pending)	I	Melanoma	GD3	sFv- $\zeta$	Harvard	Junghans




A








B


































## Coupling CD28 Co-Stimulation to Immunoglobulin T-Cell Receptor Molecules: The Dynamics of T-Cell Proliferation and Death

E. Jeffrey Beecham, Qiangzhong Ma, Robin Ripley, and Richard P. Junghans

*Biotherapeutics Development Laboratory, Division of Hematology-Oncology, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, U.S.A.*

**Summary:** Immunoglobulin T-cell receptor (IgTCR) molecules are potentially potent immune response modifiers because they allow T cells to bypass tolerance. Tolerance to self antigens has been one of the major barriers to the development of effective adoptive immunotherapies for treating cancer. In vitro studies in several laboratories have shown that cross-linking IgTCR molecules with the target antigen leads to cytolytic activity, cytokine release, and T-cell proliferation in model systems. However, many of these studies have used established T-cell lines rather than normal T cells or indirect assays of cytotoxicity, proliferation, and cytokine release. We have sought to establish the validity of these model systems while developing more effective adoptive immunotherapies using normal human T cells. In the present study the activation of T-cell proliferation after IgTCR cross-linking was evaluated. The results show that, in addition to IgTCR signals, CD28 costimulation is required to induce expansions of normal peripheral blood mononuclear cell-derived T cells. Signals from IgTCR alone can induce transient cell division, but they do not induce the prolonged polyclonal expansions that are characteristic of native immune responses. Very strong IgTCR signals could circumvent the CD28 requirement, but only at levels that are unlikely to be physiologically relevant. CD28 costimulation also suppressed the deletion of tumor-reactive subclones by activation-induced cell death. These studies confirm the importance of CD28 costimulation to the proliferation of IgTCR-modified human T cells, a key feature of an effective, reconstructed antitumor response. **Key Words:** Immunoglobulin T-cell receptor—CD28—Activation—Proliferation—Clonal selection.

The hallmarks of an effective cellular immune response are 1) cytolytic activity (cytotoxic T lymphocytes), 2) T-cell proliferation, and 3) cytokine release. Each of these T-cell functions plays an important role in determining the overall success of the response. The functions of cytotoxic T lymphocytes are responsible for physically eliminating pathogens or infected cells. Cytokines have a wide range of functions, but they generally promote the growth or differentiation of different immune cell subsets. Proliferation is crucial to the expansion

of responsive T-cell clones in numbers adequate to eliminate an infectious agent.

Immunoglobulin T-cell receptors (IgTCR) are chimeric molecules that consist of the antigen-binding portion of an antibody fused to one of the chains of the TCR. The binding properties of IgTCR molecules provide several advantages for adoptive immunotherapy to treat cancer. First, the large number of possible antibody combinations allows T-cell specificity to be assigned to virtually any antigen. Most tumor antigens are self proteins, and T cells that can recognize these self antigens have either been deleted or have become tolerant. Thus, the selection of the appropriate antibody specificity allows IgTCR molecules to bypass tolerance. A second important advantage is that IgTCR-modified T cells have

Received January 20, 2000; accepted September 5, 2000.

Address reprint requests to E. Jeffrey Beecham, Harvard Institutes of Medicine, Room 403, Beth Israel Deaconess Medical Center, 77 Avenue Louis Pasteur, Boston, MA 02115, U.S.A.

greater autonomy than normal T cells, because IgTCR-modified cells are activated directly by the immunologic target rather than through a complex process of antigen presentation by accessory cells. Finally, antigen binding is much stronger for IgTCR molecules than for the normal TCR, because antibody affinities are several orders of magnitude greater than that of a typical TCR molecule. Higher binding affinity may allow IgTCR molecules to function independently of the adhesion-costimulatory molecules usually required to facilitate normal TCR binding.

Many studies have examined the ability of IgTCR molecules to activate T cells (1–16). Direct cross-linking of the chimeric receptor by the target antigen leads to potent antigen-specific cytolytic activity (3–13,15), and the release of cytokines such as interleukin-2 (IL-2) (2, 3,5,7,13,16), interferon- $\gamma$  (7), granulocyte-macrophage-colony-stimulating factor GM-CSF (6,10), and tumor necrosis factor- $\alpha$  (1,9). In addition, two studies (7,8) have reported that IgTCR cross-linking induces T-cell proliferation. The ability of these molecules to single-handedly induce all major T-cell functions suggests that IgTCR activation may depend less on the participation of costimulatory or adhesion molecules such as CD28, LFA-1, and CD2.

When normal T cells encounter antigen, they respond in one of several ways. These reactions can include complete activation, partial activation, anergy, or the induction of apoptosis through a process called activation-induced cell death (AICD). Which reaction occurs is determined by the types of signals the cell receives. In addition to TCR ligation (signal 1), T cells usually require one or more costimulatory signals to become fully activated. The most well defined of these is delivered through the CD28 receptor (signal 2) [reviewed in Sperling and Bluestone (17) and Boussiotis et al. (18)]. When T cells do not receive CD28 costimulation, a state of unresponsiveness or anergy is usually induced (17,18). However, increasing the strength of signal 1 can lead to a reduced dependence on CD28 costimulation, with enhanced proliferation and IL-2 production in the absence of CD28 costimulation (19–23).

One implication of these studies is that the greater binding affinity of IgTCR molecules may allow them to bind tightly to antigen and transmit very strong signal 1. We examined the hypothesis that such strong IgTCR signals might reduce the dependence on CD28 and be sufficient to independently induce proliferation in normal T cells. In the current study, proliferation was examined after stimulation with different combinations of IgTCR and CD28 activation signals. The results confirm

the central role of CD28 (signal 2) for sustained *ex vivo* proliferation that can be superceded only in part by strong signal 1. These studies increase our understanding of the key immune elements necessary for designing effective antitumor T-cell gene therapies in humans.

## MATERIALS AND METHODS

### Retroviral Vector and Vector Producer Cells

The construction of anti-carcinoembryonic antigen (CEA) IgTCR genes has been previously described (15,16). The current studies were conducted with an IgTCR gene containing sequences encoding the heavy and light chain variable regions (joined by a flexible linker) from the humanized MN14 antibody fused to sequences encoding the  $\zeta$ -chain of the human TCR (16). The antibody and  $\zeta$ -chain sequences are separated by the hinge region of CD8 $\alpha$ . The anti-CEA sFv $\zeta$  construct was inserted into the MFG retroviral vector backbone, as previously described (15). Retroviral vector supernatant was produced using the PG13 producer cell line (15).

The pLNSX-hB7.1 vector (provided by Dr. Lieping Chen, Mayo Clinic, Rochester, MN, U.S.A.) contains a cDNA copy of the human B7-1 gene inserted into the LNSX vector backbone. LNSX-hB7.1 vector producer cells were constructed by transfecting the vector into GPE86 ecotropic helper cells and using the transient viral supernatant to infect the PA317 packaging cell line. PA317 cells were then selected with G418 for 10 days, after which viral supernatant was harvested and used to transduce the MIP-CEA and MIP-101 tumor cell lines.

### Lymphocyte Transduction and Culture

Peripheral blood mononuclear cells from normal blood were cultured and transduced, as previously described (15). After transduction, T cells were expanded in growth media (AIMV supplemented with 10% fetal calf serum, and 300 U/mL recombinant IL-2) until the cells reached plateau phase and the rapid cell proliferation caused by the initial OKT3-induced activation had ceased. T cells were then used in proliferation assays. Individual preparations of T-cell cultures varied slightly but generally consisted of approximately 40% to 50% IgTCR-positive cells, of which approximately 60% were CD4+ and 40% CD8+ (data not shown).

### Tumor Cell Lines and Transductions

MIP-101 is a poorly differentiated human colorectal cancer cell line that does not express CEA (24). The

MIP-CEA cell line was derived by transfecting MIP-101 with a full length cDNA encoding the human CEA gene (25). Tumor cells were cultured as previously described (15). Tumor cell lines expressing the human B7.1 gene (MIP-101.B7 and MIP-CEA.B7) were constructed by infecting parental MIP-101 and MIP-CEA cells, respectively, with a B7.1-containing retroviral vector (LNSX-hB7.1). Expression of the CEA and B7.1 proteins in tumor cells was confirmed by staining the cells with P-phycoerythrin (PE)-conjugated hMN14 and fluorescein isothiocyanate-conjugated anti-human B7.1 antibody, and then analyzing the cells by fluorescence-activated cell sorting.

### Antibodies and Flow Cytometric Analyses

Humanized MN14 (hMN14) antibody and its anti-idiotypic antibody, WI2, were obtained from Immunomedics (Morris Plains, NJ, U.S.A.). WI2 is designated as anti-IgTCR in the text. DAB9.3 is a mouse antibody against the human CD28 receptor (provided by Dr. Carl June, University of Pennsylvania, Philadelphia, PA, U.S.A.). DAB9.3 was used as a binding analog of the human B7 antigens in experiments using plate-bound antigens. OKT3 (Ortho Biotech, Raritan, NJ, U.S.A.) is a mouse antibody directed against the normal human TCR and was used as a binding analog for antigen-MHC complexes in experiments using plate-bound antigens. UPC-10 (Sigma Chemical, St. Louis, MO, U.S.A.) is a mouse antibody with binding specificity for  $\beta$ -2-6 linked fructosan and was used as a negative control staining antibody in experiments using mouse antibodies. HAT (Hoffmann-La Roche, Nutley, NJ, U.S.A.) is a humanized anti-Tac antibody and was used as a negative control staining antibody for experiments using hMN14. Anti-human B7.1 antibody was obtained from Ancell Corporation (Bayport, MN, U.S.A.). Fluorescein isothiocyanate (FITC) and PE-labeled antibodies against different human T-cell antigens (CD4, CD8) and against mouse and human Fc were obtained from Caltag Laboratories (Burlingame, CA, U.S.A.). All antibody staining reactions were performed using standard methods (26). Fluorescence intensity was measured using a Coulter (Miami, FL, U.S.A.) EPICS Profile II flow cytometer.

### T-Cell Proliferation Assays

#### *Proliferation Assays Using Plate-Bound Antigens*

Ninety-six-well tissue culture plates were coated with antibodies by incubation overnight in 0.1 mol/L sodium bicarbonate buffer (pH 7.0), followed by washing with

fresh media. Cells were added to replicate wells so that an undisturbed well could be harvested on each day for which cell counts were to be performed. At specified times, T cells were harvested from wells by vigorous pipetting to remove bound cells from the plate surface and to create a single cell suspension. Viable cells were quantified by trypan blue exclusion. When possible, a minimum of 100 cells were counted for each test sample. Individual wells were counted from two to nine times, depending on the cell density. For wells that contained a high density of cells, two duplicate counts were performed. In cases in which extensive cell death or a lack of proliferation made it difficult to obtain more than 100 cells for counting, a minimum of nine counts were done. These cell counts were averaged to obtain the total number of viable cells for each time point and treatment group in a given experiment. Cell counts from repeated independent experiments were averaged for each time point and treatment group, and the number of viable cells plotted as a function of time.

#### *Proliferation Assays Using Tumor-Bound Antigen*

Tumor cell lines were seeded into Falcon 1013 150-mm tissue culture plates and incubated overnight at 37°C to allow time for the cells to adhere and begin proliferating. Twenty-four hours later, IgTCR-modified T cells were added to the culture plates, and the plates were returned to incubation at 37°C. During tumor cell/T-cell coinubation periods, T cell growth media was used to maintain the activational state of the T cells. Both MIP-101 and MIP-CEA proliferate normally in this media. T cells and tumor cells were counted every few days by trypsinizing the plates to create single cell suspensions, mixing an aliquot of the suspension with trypan blue, and counting the cells as described above. Both MIP-101 and MIP-CEA cells are two to three times larger than human T cells and can be distinguished readily from T cells using light microscopy.

## RESULTS

The central objective of these studies was to determine which activation signals are required to induce proliferation in normal human T cells. The premise that IgTCR signals alone are sufficient for proliferation is supported by the many in vitro studies showing that IgTCR cross-linking activates all major T-cell responses (1-16). However, these previous reports of IgTCR-induced proliferation are based on increased  $^3\text{H}$ -thymidine incorporation (7,8) in IgTCR-stimulated cells.  $^3\text{H}$ -incorporation assays measure DNA replication transiently, and even high lev-

els of  $^3\text{H}$ -incorporation may not accurately reflect the logarithmic expansion of T cells that occurs during a native immune response. Furthermore, when measured early in the response, even anergizing signals that lead to abortive proliferative responses can induce levels of  $^3\text{H}$ -incorporation that are similar to those obtained with nonanergizing signals (27). In the current studies, we used direct cell counting methods rather than  $^3\text{H}$ -incorporation to measure proliferation. Our overall goal in these studies was to evaluate proliferation from an immunologically relevant perspective. This requires the ability to distinguish between true logarithmic expansions of cells and abortive proliferative responses that may involve DNA replication but which ultimately end in AICD. Direct cell counting methods are more effective than  $^3\text{H}$ -incorporation assays for accomplishing this.

As a model, we have used an IgTCR molecule directed against CEA (15,16). To distinguish between transient replication and true logarithmic expansions, we used direct cell counting methods over long periods of time. To analyze proliferation under physiologically relevant conditions, we used peripheral blood mononuclear cell-derived T cells rather than transformed T-cell lines, and antigenic stimuli were displayed on the surface of tumor cells. T cells used in the current studies were cultured for approximately 20 to 30 days before the start of any experiments so that the cultures would reach plateau phase and cease the rapid proliferation caused by the initial anti-CD3 activation. At this stage, cultures of peripheral blood mononuclear cell-derived T cells are generally in decline and consist of two populations of cells: 1) dead


and dying cells and 2) viable, resting cells. T cells that remain viable in these plateau cultures have generally returned to a resting state (in a single cell suspension of small rounded cells), but still can become reactivated when stimulated with antigen [see Beecham et al. (15)].

### Immunoglobulin T-Cell Receptor Expression in Normal Peripheral Blood T Lymphocytes

IgTCR expression in cultures of primary human T lymphocytes was measured by flow cytometric analysis. After two rounds of infection, approximately 40% to 50% of the T cells expressed the anti-CEA IgTCR gene (Fig. 1). The ratio of CD4+ and CD8+ cells in different preparations of T cells was approximately 60% CD4 and 40% CD8 (data not shown). Expression of the anti-CEA IgTCR gene was stable in long-term cultures of primary human T cells, remaining virtually unchanged for more than 2 months (data not shown). All T-cell experiments described in this report were performed using unselected populations of T cells with proportions of IgTCR-negative and IgTCR-positive cells similar to the population shown in Figure 1.

### Immunoglobulin T-Cell Receptor-Mediated Stimulation of T Cells Results in Cell Death Rather Than Proliferation

Initial experiments focused on determining whether stimulating T cells with only IgTCR signals would in-




**FIG. 1.** Normal human T lymphocytes transduced with the anti-CEA IgTCR vector. OKT3-activated human T cells were infected with the anti-CEA IgTCR vector (see the Materials and Methods section), stained with either PE-labeled W12 anti-IgTCR antibody (solid lines) or with UPC-negative control antibody (dotted lines), and then evaluated by flow cytometric analysis.


duce T-cell proliferation. Gene-modified T cells were incubated with either immobilized anti-IgTCR antibody or with MIP-CEA tumor cells (Fig. 2). In both cases, ligation of the IgTCR receptor by the target antigen led to increased T-cell death rather than proliferation. In contrast, the same T cells that were cultured in IL-2-containing media alone (not exposed to antigen) continued to proliferate slowly. Although T cells coincubated with tumor cells progressively die, they nonetheless retain potent anti-CEA cytotoxic T-lymphocyte activity for several days [see Beecham et al. (15)].

### Stimulation of T Cells Through the Immunoglobulin T-Cell Receptor and CD28 Receptors Induces Rapid and Sustained Proliferation

To determine if costimulating T cells through the IgTCR and CD28 receptors would induce T-cell proliferation, tissue culture plates were coated with anti-CD28 antibody, anti-IgTCR antibody, or both antibodies together. T cells were bound to the plates and cultured in media containing 300 U/mL recombinant IL-2. The number of viable T cells in each treatment was then measured and compared with control cultures that were not stimulated (Fig. 3). Data points are plotted as percentages of



**FIG. 2.** Signal 1 stimulation causes AICD with plate-bound or tumor-bound antigens. T cells (from the experiment described in Figure 1) were incubated in either tissue culture plates coated with anti-IgTCR antibody, in cocultures with MIP-CEA tumor cells, or in regular growth media with no antigenic stimulation as indicated in legend. Viable T cells were counted as described in Materials and Methods, and plotted as a function of time.



**FIG. 3.** The addition of signal 2 to signal 1 induces T-cell proliferation. T cells from the experiment described in Figure 1 were incubated in IL-2-containing growth media in tissue culture plates coated with anti-IgTCR antibody alone, with anti-CD28 antibody alone, with anti-IgTCR and anti-CD28 antibodies together, or in IL-2-containing media with no antigenic stimulation as indicated in the legend. Viable T cells were counted (see the Materials and Methods section), normalized to the number of cells present in the untreated controls, and plotted as percentage of controls over time.

control to normalize the cell counts for the slightly different rates of background proliferation in different replicate experiments. T cells stimulated with anti-IgTCR antibody alone (signal 1) proliferated only slightly, whereas cells stimulated with anti-CD28 alone (signal 2) showed no proliferative response. In contrast, T cells stimulated with both anti-IgTCR and anti-CD28 antibodies (signals 1 and 2) began to proliferate rapidly after approximately 5 days and continued to proliferate until the experiment was stopped on day 18. Analogous control experiments on the same cells, but using anti-CD3 antibody, with and without anti-CD28, gave virtually identical results. This shows that the IgTCR and normal TCR signaling pathways function similarly and are both influenced by the presence or absence of CD28 costimulation. It was possible to induce prolonged proliferation with signal 1 alone, but only when plates were coated with antibody concentrations significantly greater than those used in Figure 3. This is in agreement with previous studies on the normal TCRs that have shown that signal 1 alone can induce T-cell proliferation if the signal strength is strong enough (21,22).


Previous studies have indicated that immobilization of antigens on solid surfaces such as plastic culture plates can artificially increase signal strength (21–23). To measure proliferation under more physiologically relevant

conditions, a second set of experiments was performed in which ligands for signal 1 and signal 2 receptors were displayed on tumor cells. T cells were coincubated with four different tumor cell lines that displayed surface ligands that can cross-link the IgTCR molecule, the CD28 receptor, or both. To generate the appropriate tumor bound ligands, CEA-negative (MIP-101) and CEA-positive (MIP-CEA) colon carcinoma cell lines (24,25) were transduced with a retroviral vector carrying the human B7-1 gene. After selection, appropriate surface expression of the CEA and B7-1 proteins was confirmed by fluorescence-activated cell sorting (Fig. 4).


The growth curves of T cells coincubated with tumor cells expressing CEA alone (signal 1) or CEA and B7.1 (signal 1 and signal 2) are shown in Figure 5A. T cells stimulated with signals 1 and 2 slowly proliferated during the experiment. In contrast, T cells stimulated by signal 1 alone slowly decreased in number. T cells incubated with CEA-negative MIP-101 (no signal) or MIP-101-B7 tumor cells (signal 2 alone) remained relatively unchanged until the plates became overgrown with tumor and were discarded on day 8 (data not shown).

### Activation Through the Immunoglobulin T-Cell Receptor and CD28 Receptors Increases Antitumor Efficacy

The differential response of T cells to tumors expressing CEA alone or CEA and B7 was also reflected in the growth or death of the respective tumor lines themselves. Carcinoembryonic antigen-expressing tumor cells are rapidly lysed by anti-CEA IgTCR-modified T cells (15). To maintain antigenic stimulation, these cocultures were periodically fed with fresh MIP-CEA or MIP-CEA-B7 tumor cells. T cells stimulated with signal 1 alone lysed tumor cells for only 7 to 10 days before the continuous addition of tumor cells (MIP-CEA) eventually overwhelmed the lytic capacity of the T cells (Fig. 5B). After this, the tumor cells rapidly proliferate and eventually overgrow the cultures. In contrast, T cells stimulated with signal 1 and 2 (MIP-CEA-B7) were more effective at killing tumor cells (Fig. 5C). In these cocultures, MIP-CEA-B7 tumor cells were added on seven different occasions during the experiment without the outgrowth of tumor. More tumor cell killing in these cultures resulted mainly from T-cell proliferation and the ensuing maintenance of more favorable effector-to-target cell ratios.



**FIG. 4.** The human B7-1 gene was introduced into colon carcinoma cell lines. MIP-101 and MIP-CEA tumor cells were transduced with a retroviral vector containing the human B7-1 gene. The parental and transduced tumor cell lines were then stained with PE-labeled hMN14 (CEA expression as shown on the y axis), and fluorescein isothiocyanate-labeled anti-human B7-1 antibody (B7 expression as shown on the x axis), or with the appropriate negative control antibody (HAT-PE and UPC-fluorescein isothiocyanate). Fluorescence-activated cell sorting analysis of cells stained with control antibodies (not shown) were used to set the position of the quadrants in each panel. (A) Parental MIP-101 cells. (B) B7-1 transduced MIP-101 cells. (C) Parental MIP-CEA cells. (D) B7-1 transduced MIP-CEA cells.



**FIG. 5.** T cells proliferate in response to tumor cells that display various antigens. T cells from Figure 1 were cocultured with each of the tumor cell lines described in Figure 4 in IL-2-containing growth media. Cocultures were sampled at specific times and counted for both viable T cells and viable tumor cells. (A) Counts of viable T cells from cocultures with MIP-CEA or MIP-CEA-B7. Some cultures were terminated before day 27 because of tumor cell overgrowth. Counts of viable tumor cells from cocultures with MIP-CEA (B) or MIP-CEA-B7 (C). T cell numbers from panel A are separately reproduced in B and C for reference purposes.

Counts of viable tumor cells displaying no ligand (MIP-101) and only signal 2 ligand (MIP-101-B7) showed that both tumor cell lines proliferate rapidly, such that by day 8 the cultures were discarded because of the overgrowth of tumor cells (data not shown).

#### Signals 1 and 2 Act in Concert to Reduce the Total Amount of Signal Required to Activate Proliferation


Under some circumstances, T cells can be activated to proliferate by signal 1 alone (21–23). Yet, it is also clear that signal 2 plays an important role in controlling T-cell growth (Fig. 3). To define the relative roles of signals 1 and 2, proliferation assays were performed in which the strength of signal 1 was progressively increased in the presence or absence of a constant level of signal 2 (Fig. 6). This was accomplished by assaying T-cell growth in tissue culture plates coated with increasing concentrations of anti-IgTCR antibody alone (signal 1 only), or with anti-IgTCR and anti-CD28 antibodies together (signals 1 and 2). In T cells stimulated with signal 1 alone, no T-cell proliferation was observed until the anti-IgTCR antibody concentration reached very high levels (5 to 20  $\mu\text{g/mL}$ ). When T cells were stimulated with signals 1 and 2, proliferation was induced at approximately 500-fold lower levels of signal 1 (0.01 to 0.05  $\mu\text{g/mL}$ ). This shows that signal 2 decreases the amount of signal 1 required to trigger proliferation.

In both instances, proliferation was not induced until a

specific level of signal 1 strength was reached (the proliferation threshold). One interesting aspect of this analysis is that the range of antigen concentration between no growth and the maximum rate of growth was fairly broad (approximately a 100-fold increase in antigen concentration from minimum to maximum proliferative rates). Furthermore, in both cases, there appeared to be intermediate levels of proliferation within these broad proliferation-induction zones. Thus, signal strength appears to regulate the intensity of the response and its induction. The intensity of the response is finite, however, because once the maximum rate of proliferation was reached, the cells proliferate at about the same rate regardless of whether signal strength was further increased. The maximum rate of proliferation shown in Figure 6 is an approximate 40% increase in cell numbers per day. Even in the presence of adequate levels of signals 1 and 2, there is no net increase in cell number during the first 4 or 5 days (Fig. 3). The values shown in Figure 6 represent average cell growth during a 10-day period, including several days of no net growth. By day 10, maximally stimulated T cells generally doubled once every 18 h (data not shown). Thus, once a proliferative burst is underway, T-cell growth can be explosive.

These results show that T-cell proliferation is triggered by signal 1. This can be accomplished by very high levels of signal 1 alone, or at much lower levels when both signals 1 and 2 are combined. Virtually identical results were obtained in control experiments in which T






**FIG. 6.** T cells proliferated when stimulated with different antigens and at different signal strengths. T cells from the experiment described in Figure 1 were cultured in IL-2-containing growth media in tissue culture plates coated with anti-IgTCR antibody, or with anti-IgTCR and anti-CD28 antibodies together as indicated in the legend. Cultures were assayed for cell proliferation after 10 days of stimulation. Wells were coated with anti-IgTCR antibody at the concentrations shown on the x axis were admixed with either a constant amount of anti-CD28 antibody (10  $\mu$ g/mL) or with no anti-CD28 antibody. Zero values for the anti-IgTCR antibody concentration shown on the x axis represent either no antibody at all (anti-IgTCR only line) or 10  $\mu$ g/mL anti-CD28 antibody alone (anti-IgTCR + the anti-CD28 antibody line).

cells were stimulated through the normal TCR, by binding to anti-CD3 antibody alone or in combination with anti-CD28 antibody (data not shown). This indicates that both the normal and chimeric signaling pathways function in similar manners.

Although a specific level of signals 1 and 2 was required to activate proliferation, other indicators of T-cell

activation could be induced at much lower levels. In parallel to proliferation, morphologic correlates of activation were also evaluated. When resting T cells are activated, they convert from a single cell suspension of small, round cells to aggregates of large, metabolically active blast cells. Activation-induced changes in morphology were quantified by analyzing forward-scatter

**FIG. 7.** T-cell morphologic activation is controlled by signal 1. T cells from the experiment described in Figure 6 were analyzed by fluorescence-activated cell sorting for forward-scatter and log side-scatter. (A) Control cells were not exposed to antibody. (B) Cells were stimulated with IgTCR signal 1 only. (C) Cells were stimulated with signals 1 and 2 but did not proliferate (samples were treated with 0.00001 to 0.01  $\mu$ g/mL). (D) Cells stimulated with signals 1 and 2 proliferated (samples were treated with 0.05 to 5  $\mu$ g/mL). Dead and dying cells are indicated with arrows, and viable cells are circled.




and log side-scatter (FS-LSS) flow cytometric plots of cells stimulated with different signals.

Figure 7A shows the FS-LSS plot for control cells that were not stimulated with either signals 1 or 2. T cells used for these assays (Figs. 6 to 8) were obtained from plateau phase cultures that contain many dead and dying cells (arrow in Fig. 7A). T cells that remain viable in these plateau cultures have a small rounded shape (the circled population in Fig. 7A). When these same cells were stimulated with either signal 1 alone (Fig. 7B) or with signals 1 and 2, (Fig. 7C, nonproliferating cells; Fig. 7D, proliferating cells) they uniformly converted to a blast cell morphology (circled populations) regardless of whether the cells proliferated. By our evaluation, signal 2 had no effect on morphologic change. Thus, different T-cell functions are activated at different levels of signal strength. Some functions (e.g., morphologic activation) are induced by weak or incomplete signals, whereas other functions (e.g., proliferation) require stronger or more complete signals. Similar results were obtained in control experiments in which T cells were stimulated through the normal TCR alone (by anti-CD3 antibody) with and without CD28 costimulation (data not shown), showing that the IgTCR activation pathway mirrors events that occur in the normal activation pathway.

#### Selective Expansion of Immunoglobulin T-Cell Receptor-Positive Cells With Two Signals

The foregoing experiments suggest an antigen-specific deletion by AICD when T cells receive signal 1 only (Figs. 2 and 5), or an expansion of reactive clones in the presence of costimulation (Figs. 3, 5, and 6). As a test of these principles, we examined changes in the relative proportion of IgTCR-positive cells in the absence or presence of costimulation. The proportions of IgTCR-positive and -negative T cells in unselected cultures were approximately equal (see starting populations of cells in Fig. 8). T cells stimulated through the IgTCR receptor alone underwent a progressive shift to a population of cells that were predominantly IgTCR-negative (Fig. 8B). In contrast, T cells stimulated through both the IgTCR and CD28 receptors shifted to a population that was 100% IgTCR positive (Fig. 8C). As in the experiments described earlier, control experiments were again performed, in which the T cells were stimulated through the normal TCR alone (Fig. 8D) or through the normal TCR and CD28 receptors (Fig. 8E). However, in the current experiments, these control cells reacted differently from those stimulated through the chimeric receptor. T cells stimulated through the normal TCR remained virtually unchanged from the start of the experiments at an ap-



**FIG. 8.** Complete signals lead to clonal expansion of reactive clones, whereas incomplete signals induce clonal deletion by AICD. T cells were stimulated for 5 and 10 days with signal 1 only, or with signals 1 and 2 as labeled in the figure. Cells were then stained with PE-labeled anti-IgTCR antibody (solid lines) and assayed for IgTCR expression by fluorescence-activated cell sorting. Dotted lines are the negative antibody staining controls.

proximately 50:50 ratio of IgTCR-positive and -negative cells. With the normal TCR, proliferation or AICD affect IgTCR-positive and -negative populations equally, and thus does not change the proportion of positive and negative cells.

#### DISCUSSION

As one of the three major T-cell responses, antigen-induced proliferation is a critical component of cellular immunity. Antigen-specific T-cell proliferation is particularly important for adoptive immunotherapy, because several studies have shown that ex vivo modified T cells do not circulate well after infusion (28–31). This poor circulation may limit the distribution of modified cells into tumor tissues. In the absence of a proliferative response, the few cells that actually infiltrate tumor tissues may be insufficient to accomplish significant tumor reduction.

### **Inducing T-Cell Proliferation With Immunoglobulin T-Cell Receptor Molecules Requires CD28 Costimulation**

Previous studies (7,8) have reported that IgTCR cross-linking alone is sufficient to activate antigen-specific proliferation. The current study indicates that a productive expansion of IgTCR-modified cells does not generally occur unless the cells also receive CD28 costimulation. Furthermore, T-cell proliferation induced by IgTCR+CD28 activation represents a true expansion in cell number, rather than transient replication that can occur with abortive responses that end in T-cell death. Proliferation could be induced by signal 1 alone (both anti-IgTCR and anti-CD3), but only when high concentrations of cross-linking antibody was immobilized on a solid surface, similar to results obtained by others (21–23). However, these high signal strengths are unlikely to be physiologically relevant. This conclusion is supported by the lack of proliferation when T cells were incubated with MIP-CEA tumor cells. MIP-CEA tumor cells express high levels of cell surface CEA [see Beecham et al. (15)], yet they could not induce proliferation of T cells unless the tumor cells also displayed the B7-1 protein (Fig. 5A).

### **Costimulation Reduces the Level of Signal Required to Allow Proliferation**

The two-signal model holds that costimulation reduces the signaling threshold required to activate T-cell proliferation [see Sperling and Bluestone (17) and Boussiotis et al. (18)]. The current studies confirm that IgTCR-induced proliferation is similarly constrained. However, although signals 1 and 2 are required for T-cell proliferation to occur, costimulation does not lead to fully autonomous cell division. T-cell proliferation still depended on the addition of exogenous IL-2 and rapidly ceased upon IL-2 withdrawal (data not shown). This is consistent with recent reports indicating that, in addition to TCR and CD28, LFA-1 cross-linking is also required to induce the release of effective quantities of IL-2 (32,33). Although costimulation does not fulfill all signal requirements, it does appear to be essential for proliferation at physiologic levels of antigen, because its absence could not be overridden by the presence of exogenous IL-2.

Using an IgTCR molecule against prostate-specific membrane antigen, Gong et al. (34) reported that IL-2 release is induced by coupling CD28 costimulation to IgTCR signals. However, the amount of IL-2 produced in this study was only approximately 3000 pg/mL per  $10^6$  cells for 24 h (by enzyme-linked immunosorbent assay).

IL-2 release in this study also began to decrease after 48 h. IL-2 in a dose of 3000 pg/mL is equal to approximately 45 IU/mL of IL-2, which is not sufficient, in our experience, to maintain T-cell proliferation (unpublished data). Our studies use different criteria to define IL-2 release. Specifically, we use T-cell proliferation in the absence of exogenous IL-2 as a measure of the biologic consequence of endogenous IL-2 production. This is a more stringent assay readout than enzyme-linked immunosorbent assay because the T cells must synthesize and release enough endogenous IL-2 to maintain autonomous growth. It is likely that CD28 costimulation does induce the release of some endogenous IL-2, particularly because other studies have shown that CD28 costimulation plays a role in regulating the transcription and stability of IL-2 mRNA (35–37). However, our results indicate that the amount of IL2 production induced by IgTCR+CD28 cross-linking is insufficient for maintaining T-cell proliferation.

### **Incorporating CD28 Costimulation Leads to an Increase in Antitumor Efficacy**

Incorporating CD28 signaling into the IgTCR activation pathway increases the overall ability of IgTCR-modified T cells to kill tumor cells. The coculture experiments shown in Figure 5 represent an *in vitro* model of therapy in which a defined “dose” of T cells are added to tumor cells with and without costimulation. T cells stimulated by signals 1 and 2 lysed a greater total number of tumor cells and maintained their potency for a much longer period of time, whereas T cells stimulated by signal 1 alone were overwhelmed by the rapidly dividing tumor cells. Figure 5 also shows that many more tumor cells were added to the MIP-CEA-B7 cocultures than to the MIP-CEA cultures. When the difference in the number of tumor cells added, and the growth potential of those cells is considered, there is an approximately 200-fold difference in antitumor activity between T cells stimulated with signals 1 and 2 and those stimulated with signal 1 alone. The similar rates of tumor lysis, at fixed effector:target ratios, in both types of coculture have led us to conclude that the increased antitumor efficacy seen with signals 1 and 2 is a result of improved growth and survival of the T cells rather than increased activity of cytotoxic T lymphocytes on a per-cell basis. These results highlight the importance of T-cell proliferation to an effective antitumor response.

### **Individual T-Cell Effector Functions Have Individual Signaling Requirements**

Although T-cell proliferation required a minimum level of signal 1, the presence of signal 2, and exogenous

IL-2, other T-cell functions could be activated without this collaboration. When morphologic criteria are used to define T-cell activation, signal 1 is just as effective as signals 1 and 2 together, and all cells become morphologically activated regardless of whether they proliferate. This indicates that T cell activation proceeds through a stepwise progression in which signal 1 is sufficient to induce some functions while costimulation is required to turn on higher order responses such as proliferation. This makes sense in that TCR recognition (signal 1) must be the first event in the immune response and its stimulation prepares the cell (e.g., upregulation of IL-2R, CD28, LFA-1, metabolic rate, and so forth) to participate in antigen-driven proliferation.

### **Specific Signals Control T-Cell Entry Into Either an Activation-Induced Cell Death Pathway or a Selective Expansion of Reactive Clones**

Analysis of dynamic changes in the proportion of IgTCR-positive cells showed that stimulation with signal 1 alone leads to a progressive and selective deletion of antigen reactive clones (Fig. 8B, IgTCR only). These cultures were not proliferating and the conversion of the population to predominately IgTCR-negative cells resulted from the selective death of IgTCR-positive cells. In contrast, T cells stimulated with signals 1 and 2 progressively shifted from a 50:50 mixture of IgTCR-negative and IgTCR-positive cells to a population that was 100% IgTCR-positive (Fig. 8B, IgTCR+CD28) through the selective outgrowth of T cells that expressed higher levels of the receptor. Subclones that express quantitatively higher levels of receptor can generate stronger signals than subclones that express low levels of receptor simply because there are more receptors that can be cross-linked. This stronger signaling potentially provides high expressing cells with a selective advantage. When costimulation is present, this translates into a growth advantage for high expressors. When costimulation is absent, AICD results in the deletion of high expressors.

These dynamic changes are similar to events that occur during normal immune responses. Previous studies have shown that the repertoire of antigen-responsive subclones will evolve during *in vivo* T-cell expansions. This evolution involves dynamic changes in the proportions of different subclones such that the response becomes focused on specific epitopes (38–40). In some responses, this repertoire focusing is caused by the selective expansion of subclones with TCR $\alpha\beta$  chains that have higher binding affinities (41). In contrast, the evolution of high expressing IgTCR subclones in Figure 8 does not arise

because IgTCR molecules vary in their affinity for antigen. All IgTCR subclones express the same chimeric receptor with the same receptor affinity. Rather, IgTCR subclones differ in the total number of receptors expressed per cell, and high levels of receptor on specific subclones leads to stronger binding, greater signal strength, and more rapid proliferation in those clones. By this mechanism, high expressing subclones evolve to become the predominant subtypes. Thus, the end result of increased TCR cross-linking is analogous between the two systems, despite the qualitative differences between them.

In conclusion, the current study shows that CD28 costimulation is required to induce proliferation of IgTCR-stimulated human T cells. Previous reports that show <sup>3</sup>H-thymidine incorporation (7,8) after IgTCR cross-linking most likely measured transient DNA replication that can occur during abortive responses (27). Proliferative responses that occur with IgTCR and CD28 costimulation are prolonged expansions that more closely resemble what occurs during a productive native immune response. The current study also shows that IgTCR-induced activation proceeds in a stepwise manner in which weaker signals will induce morphologic activation but not proliferation. We previously showed that cytolytic functions are fully induced by IgTCR signals alone and do not require either CD28 or exogenous IL-2 (15). Thus, the first step of T-cell activation appears to involve a group of responses that include morphologic, metabolic, and cytolytic functions. Productive proliferation, on the other hand, appears to be one of the final steps of activation and requires not only signals 1 and 2 and sufficient quantities of IL-2 but also a level of signal 1 that is greater than a specific threshold. This threshold also appears to be the point at which the T cell commits to either an AICD pathway (absence of signal 2) or to a pathway of clonal expansion and affinity selection (with signal 2). Finally, the integration of CD28 costimulation into the IgTCR-activation pathway may increase antitumor responses in clinical applications of IgTCR-based immunotherapies. We are currently testing the ability of IgTCR and IgCD28 dual chimera vectors to direct antigen-specific cytolysis and proliferation. Because IL-2 is not released in this setting, a third level of activation may be required for a more complete self-sustaining antitumor response that does not require the addition of exogenous IL-2.

**Acknowledgments:** Supported by a research grant from the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.

## REFERENCES

1. Kuwana, Y., Asakura, Y., Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T cell receptor derived C regions. *Biochem Biophys Res Commun* 1987;149:960-8.
2. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cells receptor chimeric molecules as functional receptors with antibody-type specificity. *Proc Natl Acad Sci USA* 1989;86:10024-8.
3. Goverman J, Gomez S, Segesman K, Hunkapiller T, Laug W, Hood L. Chimeric immunoglobulin-T cell receptor proteins form functional receptors: implications for T cell receptor complex formation and activation. *Cell* 1990;6:929-38.
4. Romeo C, Seed B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. *Cell* 1991;4:1037-46.
5. Eshhar Z, Waks T, Gross G, Schindler D. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the  $\gamma$  or  $\zeta$  subunits of the immunoglobulin and T-cell receptors. *Proc Natl Acad Sci USA* 1993;0:720-4.
6. Hwu P, Shafer G, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor  $\gamma$  chain. *J Exper Med* 1993;178:361-6.
7. Roberts M, Qin L, Zhang D, et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. *Blood* 1994;84:2878-89.
8. Becker MLB, Near R, Mudgett-Hunter M, et al. Expression of a hybrid immunoglobulin-T cell receptor protein in transgenic mice. *Cell* 1989;58:911-21.
9. Moritz D, Wells W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. *Proc Natl Acad Sci USA* 1994;91:4318-22.
10. Weijtens MEM, Willemsen R, Valerio D, Stam K, Bolhuis R. Single chain Ig $\gamma$  gene-redirceted human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. *J Immunol* 1996;157:836-43.
11. Alteschmidt U, Kahl R, Moritz D, et al. Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes. *Clin Cancer Res* 1996;2:1001-8.
12. Yang O, Tran A-C, Kalams S, Johnson R, Roberts M, Walker B. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. *Proc Natl Acad Sci USA* 1997;94:11478-83.
13. Hombach A, Heuser C, Sircar R, et al. An anti-CD30 chimeric receptor that mediates CD3- $\zeta$ -independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. *Cancer Res* 1998;58:1116-19.
14. Hwu P, Yang J, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. *Cancer Res* 1995;55:3369-73.
15. Beecham EJ, Ortiz-Pujols S, Junghans RP. Dynamics of tumor cell killing by human T lymphocytes armed with an anti-CEA chimeric immunoglobulin T cell receptor. *J Immunother* 1999;23:332-343.
16. Nolan KF, Yun CO, Akamatsue Y, et al. Bypassing immunization: Optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. *Clin Cancer Res* 1999;5:3928-3941.
17. Sperling AI, Bluestone JA. The complexities of T cell costimulation: CD28 and beyond. *Immunol Rev* 1996;153:155-82.
18. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and downregulation of immune response. *Immunol Rev* 1996;153:5-26.
19. Green JM, Noel PJ, Sperling AI, et al. Absence of B7-dependent responses in CD28-deficient mice. *Immunity* 1994;1:501.
20. Lucas PJ, Negishi I, Nakayama K, Fields LE, Loh DY. Naive Cd28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. *J Immunol* 1995;154:5757.
21. Goldstein JS, Chen T, Brunswick M, Mostowsky H, Kozlowski S. Purified MHC class I peptide complexes activate naive CD8+ T cells independently of the CD28/B7 and LFA-1/ICAM-1 costimulatory interactions. *J Immunol* 1998;160:3180-7.
22. Luxembourg AT, Brunmark AB, Kong Y, et al. Requirements for stimulating naive CD8 T cells via signal one alone. *J Immunol* 1998;161:5226.
23. Manickasingham SP, Anderton SM, Burkhart C, Wraith DC. Qualitative and Quantitative effects of CD28/B7-mediated costimulation on naive T cell in vitro. *J Immunol* 1998;161:3827-35.
24. Niles RM, Wilhelm SA, Steele GD, et al. Isolation and characterization of an undifferentiated human colon cancer cell line (MIP-101). *Cancer Invest* 1987;5:545-52.
25. Thomas P, Gangopadhyay A, Steele G, et al. The effect of transfection of the CEA gene in the metastatic behavior of the human colorectal cancer cell line MIP-101. *Cancer Lett* 1995;92:59-66.
26. Coligan JE, Kruisbeek AM, Margulies DH, Shevack EM, Strober W, Coico R, eds. *Current Protocols in Immunology*. New York: John Wiley and Sons, 1998.
27. Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. Cd28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. *J Immunol* 1996;157:3909-17.
28. Fisher B, Packard BS, Read EJ, et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. *J Clin Oncol* 1989;7:250-61.
29. Itoh K, Sawamura Y, Hosokawa M, Kobayashi H. Scintigraphy with indium-111 labeled lymphokine-activated killer cells of malignant brain tumor. *Radiation Med* 1998;6:276-81.
30. Schafer E, Dummer R, Eilles C, et al. Imaging pattern of radiolabeled lymphokine activated killer cells in patients with metastatic malignant melanoma. *Eur J Nucl Med* 1991;18:106-10.
31. Schwartzentruber DJ, Hom SS, et al. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. *J Clin Oncol* 1994;12:1475-83.
32. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MGO, Schlom J. A triad of costimulatory molecules synergize to amplify T cell activation. *Cancer Res* 1999;59:5800-7.
33. Sprent J. Stimulating naive T cells. *J Immunol* 1999;163:4629-36.
34. Gong MC, Latouche J-B, Krause A, Heston WDW, Bander NH, Sadelain M. Cancer patients T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. *Neoplasia* 1999;1:123-7.
35. Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. *Science* 1991;251:313.
36. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen specific IL2 production by human T cells. *J Immunol* 1991;147:2461.
37. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. *Science* 1989;244:339.
38. Mcheyzer-Williams MG, Davis MM. Antigen-specific development of primary and memory T cells in vivo. *Science* 1995;268:106-11.
39. Bachmann MF, Speiser DE, Ohashi PS. Functional maturation of and antiviral cytotoxic T cell response. *J Virol* 1997;71:5764-68.
40. Busch DH, Pilip I, Pamer EG. Evolution of a complex TCR repertoire during primary and recall bacterial infection. *J Exp Med* 1998;188:61-70.
41. Busch DH, Pamer EG. T cell affinity maturation by selective expansion during infection. *J Exp Med* 1999;189:701-9.